

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 51/08	A2	(11) International Publication Number: WO 97/33627
		(43) International Publication Date: 18 September 1997 (18.09.97)

(21) International Application Number: PCT/US97/03915

(22) International Filing Date: 12 March 1997 (12.03.97)

(30) Priority Data:

60/013,360	13 March 1996 (13.03.96)	US
08/646,866	8 May 1996 (08.05.96)	US
08/808,699	28 February 1997 (28.02.97)	US

(71) Applicant: THE DU PONT MERCK PHARMACEUTICAL COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).

(72) Inventors: EDWARDS, David, Scott; 123 Farms Drive, Burlington, MA 01803 (US). LIU, Shuang; 17 Judith Road, Chelmsford, MA 01824 (US).


(74) Agent: BOUDREAUX, Gerald, J.; The du Pont Merck Pharmaceutical Company, Legal/Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: NEW TERNARY RADIOPHARMACEUTICAL COMPLEXES



(57) Abstract

This invention relates to novel radiopharmaceuticals which are useful as imaging agents for the diagnosis of cardiovascular disorders, infectious disease and cancer, and to kits useful for their preparation. The radiopharmaceuticals of this invention are comprised of a transition metal radionuclide, a transition metal chelator, a biologically active group connected to said chelator, a first ancillary ligand, a second ancillary ligand capable of stabilizing the radiopharmaceutical, optionally having a linking group between said chelator and said biologically active group. Preferred radiopharmaceuticals of this invention have the formula: $[(Q)_d \text{Ln} \text{Ch}]_x \text{M}_1(\text{AL}_1)_y (\text{AL}_2)_z$, wherein the shown variables are as defined herein.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

TITLE

New Ternary Radiopharmaceutical Complexes

5

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is related to our copending application U.S.S.N. 08/415,908, which is a
10 continuation-in-part of U.S.S.N. 08/218,861 which is a continuation-in-part of U.S.S.N. 08/040,336 filed March 30, 1993, the disclosures of which are incorporated herein by reference.

15

FIELD OF THE INVENTION

This invention relates to novel radiopharmaceuticals which are useful as imaging agents for the diagnosis of cardiovascular disorders,
20 infectious disease and cancer, and to kits useful for their preparation. The radiopharmaceuticals are comprised of nitrogen-containing heterocycle ligated technetium-99m labeled hydrazino or diazino modified biologically active molecules that selectively localize
25 at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy.

BACKGROUND OF THE INVENTION

30 There is a current need for new methods for the non-invasive diagnosis of a variety of diseases such as thromboembolic disease, atherosclerosis, infection and cancer. Radiopharmaceuticals comprised of gamma-ray emitting radionuclide labeled biologically active
35 molecules can fulfill the need. The biologically active molecules serve to localize the radionuclides at the sites of disease and thus allow the sites to be

visualized by gamma scintigraphy. The molecules can be either proteins, antibodies, antibody fragments, peptides or polypeptides, or peptidomimetics. The molecules interact with a receptor or binding site
5 expressed at the sites of the disease or with a receptor or binding site on an endogenous blood component, such as platelets and leukocytes, that accumulate at the sites. This interaction results in selective localization of a percentage of the injected
10 radiopharmaceutical while the remainder is cleared either through the renal or hepatobiliary systems. The localized radiopharmaceutical is then imaged externally using gamma scintigraphy. The relative rates of sequestration, clearance and radionuclidic decay
15 determine the ease of visualization, often expressed as the target-to-background ratio. Frequently, only certain portions of the biologically active molecules bind to the receptors; these portions are termed the recognition sequences or units.

20

A number of radiopharmaceuticals comprised of radionuclide labeled proteins, antibodies or antibody fragments are under development, however, to date only one has been approved by the Food and Drug
25 Administration. This sparse record results from a combination of factors that make developing these radiopharmaceuticals difficult, including problems with manufacturing and quality control, non-optimal sequestration and clearance rates, and the occurrence of
30 antigenic or allergic responses to the radiopharmaceuticals. These problems are mainly due to the macromolecular nature of the proteins, antibodies and antibody fragments. Their high molecular weight makes direct chemical synthesis impractical, therefore
35 they must be synthesized by recombinant or cloning techniques that typically give low yields and require extensive isolation and purification procedures. Their

molecular weight can slow their rates of localization and preclude their clearance by an active elimination mechanism via the kidneys or liver, resulting in prolonged retention in the circulation which causes a high background level during imaging. Also, the body's immune system tends to recognize more efficiently larger exogenous species.

The use of lower molecular weight peptides, polypeptides or peptidomimetics as the biologically active molecules obviates a number of these problems. These molecules can be synthesized directly using classical solution chemistry or by an automated peptide synthesizer. They can be formed in higher yields and require less complicated purification procedures. They tend to clear more rapidly from the circulation by an active elimination pathway resulting in a lower background in the images. They are also usually not immunogenic. The first radionuclide labeled polypeptide radiopharmaceutical has been recently approved by the Food and Drug Administration.

There are two general methods for labeling biologically active molecules with radionuclides for use as radiopharmaceuticals termed direct and indirect labeling. Direct labeling involves attaching the radionuclide to atoms on the biologically active molecule; while the indirect method involves attaching the radionuclide via a chelator. The chelator can either be attached to the biologically active molecule prior to reaction with the radionuclide or the radionuclide labeled chelator moiety can be attached to the biologically active molecule. Several recent reviews describe these labeling methods and are incorporated herein by reference: S. Jurisson et. al., Chem. Rev., 1993, 93, 1137; A. Verbruggen, Eur. J. Nuc. Med., 1990,

17, 346; and M. Derwanjee, Semin. Nuc. Med., 1990, 20, 5.

5 The use of hydrazines and hydrazides as chelators to modify proteins for labeling with radionuclides has been recently disclosed in Schwartz et. al., U.S. Patent 5,206,370. For labeling with technetium-99m, the hydrazino-modified protein is reacted with a reduced technetium species, formed by reacting pertechnetate
10 with a reducing agent in the presence of a chelating dioxygen ligand. The technetium becomes bound to the protein through what are believed to be hydrazido or diazenido linkages with the coordination sphere completed by the ancillary dioxygen ligands. Examples of
15 ancillary dioxygen ligands include glucoheptonate, gluconate, 2-hydroxyisobutyrate, and lactate.

Certain dioxygen ligands have been recently reported to be particularly advantageous for labeling
20 hydrazino-modified proteins with technetium-99m. Bridger et. al., U. S. Patent 5,350,837, disclose a series of functionalized aminocarboxylates the use of which are reported to improve the labeling process of hydrazino-modified macromolecules such as monoclonal antibodies.
25 The improvements are manifest by shorter reaction times and higher specific activities. Examples of these improved dioxygen ligands include hydroxyalkyl substituted glycine derivatives such as tricine.

30 In co-pending U.S. Ser. No. 08/218,861 (equivalent to WO 94/22494) , filed March 28, 1994, the synthesis of novel radiolabeled platelet IIb/IIIa receptor antagonists as imaging agents for thromboembolic disorders is disclosed. These reagents comprise
35 radionuclide labeled chelator modified cyclic compounds. A preferred chelator for modifying the cyclic compounds is the hydrazino or diazenido moiety.

The preferred reagents are used to synthesize binary complexes comprised of the hydrazido or diazenido moiety and one of a series of ancillary ligands.

5

SUMMARY OF THE INVENTION

This invention provides novel radiopharmaceuticals which are useful as imaging agents for the diagnosis of cardiovascular disorders, such as thromboembolic disease or atherosclerosis, infectious disease and cancer. The radiopharmaceuticals are comprised of nitrogen-containing heterocycle ligated technetium-99m labeled hydrazino or diazenido modified biologically active molecules that selectively localize at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy. The invention also provides methods of using said radiopharmaceuticals as imaging agents for the diagnosis of cardiovascular disorders, such as thromboembolic disease or atherosclerosis, infectious disease and cancer. It further provides kits for the preparation of said radiopharmaceuticals.

Brief Description of the Figures

25

Figure 1. Data from the Canine Arteriovenous Shunt model for the Radiopharmaceutical of Example 1 (150 $\mu\text{Ci/kg, i.v.}$), compared to ^{111}In -platelets, ^{125}I -fibrinogen and $^{99\text{m}}\text{Tc}$ -albumin.

30

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to novel radiopharmaceuticals for the diagnosis of cardiovascular disorders, such as thromboembolic disease and atherosclerosis, infectious disease or cancer of

the formula $[(Q)_{d'}L_n-Ch']_x-M_t(AL_1)_y(AL_2)_z$, methods of using said radiopharmaceuticals in the diagnosis of diseases and kits useful for the preparation of said radiopharmaceutical.

5

[1] One embodiment of the present invention is a radiopharmaceutical comprising a first ancillary ligand, a second ancillary ligand capable of stabilizing the radiopharmaceutical, a transition metal radionuclide, a transition metal chelator, a biologically active group connected to said chelator, optionally having a linking group between said chelator and said biologically active group.


10

[2] Preferred radiopharmaceuticals of this invention are those having a linking group between said chelator and said biologically active group.

15

[3] More preferred radiopharmaceuticals of this invention are those of formula:

20



and pharmaceutically acceptable salts thereof wherein,


25

Q is a biologically active group;

d' is 1 to 20;

30

L_n is a linking group of formula:



wherein:

5 M^1 is $-[(CH_2)_g Z^1]_{g'} - (CR^{55}R^{56})_{g''}$;

M^2 is $-(CR^{55}R^{56})_{g''} - [Z^1(CH_2)_g]_{g'}$;

g is independently 0-10;

10 g' is independently 0-1;

g'' is independently 0-10;

15 f is independently 0-10;

f' is independently 0-10;

f'' is independently 0-1;

20 Y^1 and Y^2 , at each occurrence, are independently selected from:

25 a bond, O, NR^{56} , $C=O$, $C(=O)O$, $OC(=O)O$, $C(=O)NH-$, $C=NR^{56}$, S, SO, SO_2 , SO_3 , $NHC(=O)$, $(NH)_2C(=O)$, $(NH)_2C=S$;

30 Z^1 is independently selected at each occurrence from a C_6-C_{14} saturated, partially saturated, or aromatic carbocyclic ring system, substituted with 0-4 R^{57} ; and a heterocyclic ring system, optionally substituted with 0-4 R^{57} ;

35 R^{55} and R^{56} are independently selected at each occurrence from:

hydrogen, C₁-C₁₀ alkyl substituted with 0-5 R⁵⁷, alkaryl wherein the aryl is substituted with 0-5 R⁵⁷;

5

R⁵⁷ is independently selected at each occurrence from the group: hydrogen, OH, NHR⁵⁸, C(=O)R⁵⁸, OC(=O)R⁵⁸, OC(=O)OR⁵⁸, C(=O)OR⁵⁸, C(=O)NR⁵⁸, C≡N, SR⁵⁸, SOR⁵⁸, SO₂R⁵⁸, NHC(=O)R⁵⁸, NHC(=O)NHR⁵⁸, NHC(=S)NHR⁵⁸, or, alternatively, when attached to an additional molecule Q, R⁵⁷ is independently selected at each occurrence from the group: O, NR⁵⁸, C=O, C(=O)O, OC(=O)O, C(=O)N, C=NR⁵⁸, S, SO, SO₂, SO₃, NHC(=O), (NH)₂C(=O), (NH)₂C=S; and

10

15

20

R⁵⁸ is independently selected at each occurrence from the group: hydrogen, C₁-C₆ alkyl, benzyl, and phenyl;

25

x, y and z are independently 1 or 2;

M_t is a transition metal radionuclide selected from the group: ^{99m}Tc, ¹⁸⁶Re and ¹⁸⁸Re;

30

Ch⁺ is a radionuclide metal chelator coordinated to transition metal radionuclide M_t, and is independently selected at each occurrence, from the group: R⁴⁰N=N⁺=, R⁴⁰R⁴¹N-N=, and R⁴⁰N=N(H)-; wherein

35

5 R⁴⁰ is independently selected at each occurrence from the group: a bond to L_n, C₁-C₁₀ alkyl substituted with 0-3 R⁵², aryl substituted with 0-3 R⁵², cycloalkyl substituted with 0-3 R⁵², heterocycle substituted with 0-3 R⁵², heterocycloalkyl substituted with 0-3 R⁵², aralkyl substituted with 0-3 R⁵² and alkaryl substituted with 0-3 R⁵²;

10 R⁴¹ is independently selected from the group: hydrogen, aryl substituted with 0-3 R⁵², C₁-C₁₀ alkyl substituted with 0-3 R⁵², and a heterocycle substituted with 0-3 R⁵²;

15 R⁵² is independently selected at each occurrence from the group: a bond to L_n, =O, F, Cl, Br, I, -CF₃, -CN, -CO₂R⁵³, -C(=O)R⁵³, -C(=O)N(R⁵³)₂, -CHO, -CH₂OR⁵³, -OC(=O)R⁵³, -OC(=O)OR^{53a}, -OR⁵³, -OC(=O)N(R⁵³)₂, -NR⁵³C(=O)R⁵³, -N(R⁵³)₃⁺, -NR⁵⁴C(=O)OR^{53a}, -NR⁵³C(=O)N(R⁵³)₂, -NR⁵⁴SO₂N(R⁵³)₂, -NR⁵⁴SO₂R^{53a}, -SO₃H, -SO₂R^{53a}, -SR⁵³, -S(=O)R^{53a}, -SO₂N(R⁵³)₂, -N(R⁵³)₂, -NHC(=NH)NHR⁵³, -C(=NH)NHR⁵³, =NOR⁵³, NO₂, -C(=O)NHOR⁵³, -C(=O)NHN(R⁵³)R^{53a}, -OCH₂CO₂H, 2-(1-morpholino)ethoxy;

25 R⁵³, R^{53a}, and R⁵⁴ are each independently selected at each occurrence from the group: hydrogen, C₁-C₆ alkyl, and a bond to L_n;


30 A_{L1} is a first ancillary ligand selected from the group:

dioxygen ligand and
functionalized aminocarboxylate;

5

A_{L2} is an ancillary ligand capable of stabilizing
the radiopharmaceutical selected from the
group:

10



wherein

15

n is 0 or 1;

X^1 is independently selected at each
occurrence from the group: CR^{64} and
 N ;

20

X^2 is independently selected at each
occurrence from the group: CR^{64} ,
 $CR^{64}R^{64}$, N , NR^{64} , O and S ;

25

X^3 is independently selected at each
occurrence from the group: C , CR^{64} ,
and N ;

30

provided the total number of heteroatoms
in each ring of the ligand A_{L2} is 1
to 4;

Y is selected from the group: BR^{64} -,
 CR^{64} , $(\text{P}=\text{O})$, $(\text{P}=\text{S})$;

5 and a, b, c, d, e and f indicate the
positions of optional double
bonds, provided that one of e and f
is a double bond;

10 R^{64} is independently selected at each
occurrence from the group:

15 H, C_1 - C_{10} alkyl substituted
with 0-3 R^{65} , C_2 - C_{10} alkenyl
substituted with 0-3 R^{65} , C_2 -
 C_{10} alkynyl substituted with 0-
3 R^{65} , aryl substituted with 0-
3 R^{65} , carbocycle substituted
with 0-3 R^{65} , and R^{65} ;

20

or, alternatively, two R^{64} may be
taken together with the atom
or atoms to which they are
25 attached to form a fused
aromatic, carbocyclic or
heterocyclic ring, substituted
with 0-3 R^{65} ;

30

R^{65} is independently selected
at each occurrence from
the group: $=\text{O}$, F, Cl,
Br, I, $-\text{CF}_3$, $-\text{CN}$, $-\text{NO}_2$,
35 $-\text{CO}_2\text{R}^{66}$, $-\text{C}(=\text{O})\text{R}^{66}$,
 $-\text{C}(=\text{O})\text{N}(\text{R}^{66})_2$, $-\text{N}(\text{R}^{66})_3^+$,
 $-\text{CH}_2\text{OR}^{66}$, $-\text{OC}(=\text{O})\text{R}^{66}$,

5
 10
 15
 20
 25
 30
 35

-OC(=O)OR^{66a}, -OR⁶⁶,
 -OC(=O)N(R⁶⁶)₂,
 -NR⁶⁶C(=O)R⁶⁶,
 -NR⁶⁷C(=O)OR^{66a},
 -NR⁶⁶C(=O)N(R⁶⁶)₂,
 -NR⁶⁷SO₂N(R⁶⁶)₂,
 -NR⁶⁷SO₂R^{66a}, -SO₃H,
 -SO₂R^{66a}, -SO₂N(R⁶⁶)₂,
 -N(R⁶⁶)₂, -OCH₂CO₂H; and

R⁶⁶, R^{66a}, and R⁶⁷ are each
 independently selected at
 each occurrence from the
 group: hydrogen and C₁-C₆
 alkyl.

[4] Also more preferred are the radiopharmaceuticals of
 this invention wherein:

Q is a biologically active molecule selected from
 the group: IIb/IIIa receptor antagonists,
 IIb/IIIa receptor ligands, fibrin binding
 peptides, leukocyte binding peptides,
 chemotactic peptides, somatostatin analogs,
 and selectin binding peptides;

d' is 1 to 3;

L_n is:

- (CR⁵⁵R⁵⁶)_g- [Y¹(CR⁵⁵R⁵⁶)_fY²]_f- (CR⁵⁵R⁵⁶)_g- ,

wherein:

g^{*} is 0-5;

f is 0-5;

f' is 1-5;

y¹ and y², at each occurrence, are independently selected from:

O, NR⁵⁶, C=O, C(=O)O, OC(=O)O, C(=O)NH, C=NR⁵⁶, S, SO, SO₂, SO₃, NHC(=O), (NH)₂C(=O), (NH)₂C=S;

R⁵⁵ and R⁵⁶ are independently selected at each occurrence from:

hydrogen, C₁-C₁₀ alkyl and alkaryl;

x and y are 1;

M_t is ^{99m}Tc;

Ch is selected from the group: R⁴⁰N=N⁺= and R⁴⁰R⁴¹N-N=; wherein

R⁴⁰ is independently selected at each occurrence from the group: aryl substituted with 0-3 R⁵², and heterocycle substituted with 0-3 R⁵²;

R⁴¹ is independently selected from the group: hydrogen, aryl substituted with 0-1 R⁵², C₁-C₃ alkyl substituted with 0-1 R⁵², and a heterocycle substituted with 0-1 R⁵²;

5 R^{52} is independently selected at each occurrence from the group: a bond to L_n , $-CO_2R^{53}$, $-CH_2OR^{53}$, $-SO_3H$, $-SO_2R^{53a}$, $-N(R^{53})_2$, $-N(R^{53})_3^+$, $-NHC(=NH)NHR^{53}$, and $-OCH_2CO_2H$;

10 R^{53} and R^{53a} are each independently selected at each occurrence from the group: hydrogen and C_1 - C_3 alkyl;

15 AL_1 is a functionalized aminocarboxylate;

n is 0;

20 Y is BR^{64-} ;

R^{64} is independently selected at each occurrence from the group:

25 H , C_1 - C_3 alkyl substituted with 0-3 R^{65} , aryl substituted with 0-3 R^{65} , and R^{65} ;

30 or, alternatively, two R^{64} may be taken together with the atom or atoms to which they are attached to form a fused aromatic or heterocyclic ring, substituted with 0-3 R^{65} ;

35 R^{65} is independently selected at each occurrence from the group: $-NO_2$, $-CO_2R^{66}$, $-OR^{66}$, $-SO_3H$, and $-OCH_2CO_2H$; and

R⁶⁶ is hydrogen.

- 5 [5] Most preferred are those radiopharmaceuticals of this invention wherein:

10 Q is a biologically active molecule selected from the group: IIb/IIIa receptor antagonists and chemotactic peptides;

d' is 1;

15 Y¹ and Y², at each occurrence, are independently selected from:

20 O, NR⁵⁶, C=O, C(=O)O, OC(=O)O, C(=O)NH, C=NR⁵⁶, NHC(=O), (NH)₂C(=O);

R⁵⁵ and R⁵⁶ are hydrogen;

25 z is 1;

R⁴⁰ is heterocycle substituted with R⁵²;

30 R⁴¹ is hydrogen;

R⁵² is a bond to L_n;

A_{L1} is tricine;

35 X² is independently selected at each occurrence from the group: CR⁶⁴, CR⁶⁴R⁶⁴, N, NR⁶⁴ and O;

X³ is N;

provided the total number of heteroatoms
in each ring of the ligand A_{L2} is 2
to 3;


R⁶⁴ is independently selected at each
occurrence from the group:

H, C₁-C₃ alkyl substituted
with 0-1 R⁶⁵, aryl substituted
with 0-1 R⁶⁵;
and R⁶⁵;

R⁶⁵ is independently selected at
each occurrence from the
group: -NO₂, -CO₂R⁶⁶,
-OR⁶⁶, and -SO₃H.

[6] Specifically preferred radiopharmaceuticals are
those wherein:



Q is




d' is 1;

L_n is attached to Q at the carbon atom designated with a * and has the formula:

5



or



Ch is

is attached to L_n at the carbon atom designated with a *;

10



M_t is ^{99m}Tc ;

AL_1 is tricine;







15

x , y and z are 1;


and AL_2 is selected from the group:



20



25



5

and

[7] Another embodiment of this invention is a method for radioimaging a mammal comprising (i) administering to said mammal an effective amount of a radiopharmaceutical of any of Claims 1-6, and (ii) scanning the mammal using a radioimaging device.


[8] Another embodiment of this invention is a method for visualizing sites of platelet deposition in a mammal by radioimaging, comprising (i) administering to said mammal an effective amount of a radiopharmaceutical of any of Claims 1-6, and (ii) scanning the mammal using a radioimaging device.

[9] Another embodiment of this invention is a method of determining platelet deposition in a mammal comprising administering to said mammal a radiopharmaceutical composition of any of Claims 1-6, and imaging said mammal.

[10] Another embodiment of this invention is a method of diagnosing a disorder associated with platelet deposition in a mammal comprising administering to said mammal a radiopharmaceutical composition of any of Claims 1-6, and imaging said mammal.

[11] Another embodiment of this invention is a kit for preparing a radiopharmaceutical comprising:


(a) a predetermined quantity of a sterile, pharmaceutically acceptable reagent of formula:



(b) a predetermined quantity of a sterile, pharmaceutically acceptable first ancillary ligand, AL_1 , selected from the group:

dioxygen ligand and
functionalized aminocarboxylate;

(c) a predetermined quantity of a sterile, pharmaceutically acceptable second ancillary ligand, AL_2 , selected from the group:



(d) a predetermined quantity of a sterile, pharmaceutically acceptable reducing agent;
and


(e) optionally, a predetermined quantity of one or more sterile, pharmaceutically acceptable components selected from the group: transfer
 5 ligands, buffers, lyophilization aids, stabilization aids, solubilization aids and bacteriostats;

wherein:

10 Q is a biologically active molecule;

d' is 1 to 20;

15 L_n is a linking group of formula:



20 wherein:

M^1 is $-[(CH_2)_g Z^1]_{g'} - (CR^{55}R^{56})_{g''} -$;

25 M^2 is $-(CR^{55}R^{56})_{g''} - [Z^1 (CH_2)_g]_{g'} -$;

g is independently 0-10;

g' is independently 0-1;

30 g'' is independently 0-10;

f is independently 0-10;

35 f' is independently 0-10;

f'' is independently 0-1;

y¹ and y², at each occurrence, are independently selected from:

5 a bond, O, NR⁵⁶, C=O, C(=O)O, OC(=O)O, C(=O)NH-, C=NR⁵⁶, S, SO, SO₂, SO₃, NHC(=O), (NH)₂C(=O), (NH)₂C=S;

10 z¹ is independently selected at each occurrence from a C₆-C₁₄ saturated, partially saturated, or aromatic carbocyclic ring system, substituted with 0-4 R⁵⁷, and a
15 heterocyclic ring system, optionally substituted with 0-4 R⁵⁷;

R⁵⁵ and R⁵⁶ are independently selected at each occurrence from:

20 hydrogen; C₁-C₁₀ alkyl substituted with 0-5 R⁵⁷, alkaryl wherein the aryl is substituted with 0-5 R⁵⁷;

25 R⁵⁷ is independently selected at each occurrence from the group: hydrogen, OH, NHR⁵⁸, C(=O)R⁵⁸, OC(=O)R⁵⁸, OC(=O)OR⁵⁸, C(=O)OR⁵⁸, C(=O)NR⁵⁸, C≡N, SR⁵⁸, SOR⁵⁸,
30 SO₂R⁵⁸, NHC(=O)R⁵⁸, NHC(=O)NHR⁵⁸, NHC(=S)NHR⁵⁸; or, alternatively, when attached to an additional molecule Q, R⁵⁷ is independently selected at each occurrence from
35 the group: O, NR⁵⁸, C=O, C(=O)O, OC(=O)O, C(=O)N, C=NR⁵⁸, S, SO,

SO₂, SO₃, NHC(=O), (NH)₂C(=O),
(NH)₂C=S; and,

5 R⁵⁸ is independently selected at each
occurrence from the group:
hydrogen, C₁-C₆ alkyl, benzyl, and
phenyl;

10 C_h is a radionuclide metal chelator selected from
the group: R⁴⁰R⁴¹N-N=C(C₁-C₃ alkyl)₂ and
R⁴⁰NNH₂-, and R⁴⁰R⁴¹N-N=CR⁸⁰R⁸¹, wherein,

15 R⁴⁰ is independently selected at each
occurrence from the group: a bond
to L_n, C₁-C₁₀ alkyl substituted with
0-3 R⁵², aryl substituted with 0-3
R⁵², cycloalkyl substituted with 0-3
R⁵², heterocycle substituted with 0-
20 3 R⁵², heterocycloalkyl substituted
with 0-3 R⁵², aralkyl substituted
with 0-3 R⁵² and alkaryl substituted
with 0-3 R⁵²;

25 R⁴¹ is independently selected from the
group: hydrogen, aryl substituted
with 0-3 R⁵², C₁-C₁₀ alkyl
substituted with 0-3 R⁵², and a
heterocycle substituted with 0-3
R⁵²;


30 R⁵² is independently selected at each
occurrence from the group: a bond
to L_n, =O, F, Cl, Br, I, -CF₃, -CN,
-CO₂R⁵³, -C(=O)R⁵³, -C(=O)N(R⁵³)₂,
35 -CHO, -CH₂OR⁵³, -OC(=O)R⁵³,
-OC(=O)OR^{53a}, -OR⁵³, -OC(=O)N(R⁵³)₂,
-NR⁵³C(=O)R⁵³, -NR⁵⁴C(=O)OR^{53a},

5
 -N(R⁵³)₃⁺, -NR⁵³C(=O)N(R⁵³)₂,
 -NR⁵⁴SO₂N(R⁵³)₂, -NR⁵⁴SO₂R^{53a},
 -SO₃H, -SO₂R^{53a}, -SR⁵³, -S(=O)R^{53a},
 -SO₂N(R⁵³)₂, -N(R⁵³)₂,
 -NHC(=NH)NHR⁵³, -C(=NH)NHR⁵³,
 =NOR⁵³, NO₂, -C(=O)NHR⁵³,
 -C(=O)NHN(R⁵³)R^{53a}, -OCH₂CO₂H,
 2-(1-morpholino)ethoxy;

10
 R⁵³, R^{53a}, and R⁵⁴ are each independently
 selected at each occurrence from
 the group: hydrogen, C₁-C₆ alkyl,
 and a bond to L_n;

15
 R⁸⁰ and R⁸¹ are independently selected
 from the group:
 H, C₁-C₁₀ alkyl, -CN, -CO₂R⁸⁵,
 -C(=O)R⁸⁵, -C(=O)N(R⁸⁵)₂, C₂ - C₁₀ 1-
 20 alkene substituted with 0-3 R⁸⁴, C₂
 - C₁₀ 1-alkyne substituted with 0-3
 R⁸⁴, aryl substituted with 0-3 R⁸⁴,
 unsaturated heterocycle substituted
 with 0-3 R⁸⁴, and unsaturated
 25 carbocycle substituted with 0-3 R⁸⁴,
 provided that when one of R⁸⁰ and
 R⁸¹ is H or alkyl, then the other is
 not H or alkyl;

30
 or, alternatively, R⁸⁰ and R⁸¹, may be
 taken together with the shown
 divalent carbon radical to form:



wherein:

R⁸² and R⁸³ may be independently

selected from the group:

H, R⁸⁴, C₁-C₁₀ alkyl

substituted with 0-3 R⁸⁴, C₂-

C₁₀ alkenyl substituted with

0-3 R⁸⁴, C₂-C₁₀ alkynyl

substituted with 0-3 R⁸⁴, aryl

substituted with 0-3 R⁸⁴,

heterocycle substituted with

0-3 R⁸⁴ and carbocycle

substituted with 0-3 R⁸⁴;

or, alternatively, R⁸², R⁸³ may be
taken together to form a fused
aromatic or heterocyclic ring;

R⁸⁴ is independently selected

at each occurrence from

the group: =O, F, Cl,

Br, I, -CF₃, -CN, -CO₂R⁸⁵,

-C(=O)R⁸⁵, -C(=O)N(R⁸⁵)₂,

-N(R⁸⁵)₃⁺, -CH₂OR⁸⁵,

-OC(=O)R⁸⁵, -OC(=O)OR^{85a},

-OR⁸⁵, -OC(=O)N(R⁸⁵)₂,

-NR⁸⁵C(=O)R⁸⁵,

-NR⁸⁶C(=O)OR^{85a},

-NR⁸⁵C(=O)N(R⁸⁵)₂,

-NR⁸⁶SO₂N(R⁸⁵)₂,

-NR⁸⁶SO₂R^{85a}, -SO₃H,

-SO₂R^{85a}, -SR⁸⁵,

-S(=O)R^{85a}, -SO₂N(R⁸⁵)₂,

-N(R⁸⁵)₂, -NHC(=NH)NHR⁸⁵,

-C(=NH)NHR⁸⁵, =NOR⁸⁵,

-C(=O)NHO^{R85}, -OCH₂CO₂H,
2-(1-morpholino)ethoxy;
and

5

R⁸⁵, R^{85a}, and R⁸⁶ are each
independently selected at
each occurrence from the
group: hydrogen and C₁-C₆
alkyl.

10

X¹ is independently selected at each
occurrence from the group: CR⁶⁴ and
N;

15

X² is independently selected at each
occurrence from the group: CR⁶⁴,
CR⁶⁴R⁶⁴, N, NR⁶⁴, O and S;

20

X³ is independently selected at each
occurrence from the group: C, CR⁶⁴,
and N;

25

Y is selected from the group: BR⁶⁴-,
CR⁶⁴, (P=O), (P=S);

provided the total number of heteroatoms
in each ring of the heterocycle is
1 to 4;

30

R⁶⁴ is independently selected at each
occurrence from the group:

35

H, C₁-C₁₀ alkyl substituted
with 0-3 R⁶⁵, C₂ - C₁₀ alkenyl
substituted with 0-3 R⁶⁵, C₂ -
C₁₀ alkynyl substituted with 0-

3 R⁶⁵, aryl substituted with 0-
3 R⁶⁵, carbocycle substituted
with 0-3 R⁶⁵ and R⁶⁵;

5

or, alternatively, two R⁶⁴ may be
taken together with the atom
or atoms to which they are
attached to form a fused
aromatic, carbocyclic or
heterocyclic ring, substituted
with 0-3 R⁶⁵;

10

15

R⁶⁵ is independently selected
at each occurrence from
the group: =O, F, Cl,
Br, I, -CF₃, -CN, -NO₂,
-CO₂R⁶⁶, -C(=O)R⁶⁶,
-C(=O)N(R⁶⁶)₂, -N(R⁶⁶)₃⁺
-CH₂OR⁶⁶, -OC(=O)R⁶⁶,
-OC(=O)OR^{66a}, -OR⁶⁶,
-OC(=O)N(R⁶⁶)₂,
-NR⁶⁶C(=O)R⁶⁶,
-NR⁶⁷C(=O)OR^{66a},
-NR⁶⁶C(=O)N(R⁶⁶)₂,
-NR⁶⁷SO₂N(R⁶⁶)₂,
-NR⁶⁷SO₂R^{66a}, -SO₃H,
-SO₂R^{66a}, -SO₂N(R⁶⁶)₂,
-N(R⁶⁶)₂, -OCH₂CO₂H; and

20

25

30

R⁶⁶, R^{66a}, and R⁶⁷ are each
independently selected at
each occurrence from the
group: hydrogen and C₁-C₆
alkyl.

35

n is 0 or 1;

and a, b, c, d, e and f indicate the
positions of optional double bonds,
provided that one of e and f.

[12] Preferred kits of this invention are those wherein:

AL1 is a functionalized aminocarboxylate;

Q is a biologically active molecule selected from
the group: IIb/IIIa receptor antagonists,
IIb/IIIa receptor ligands, fibrin binding
peptides, leukocyte binding peptides,
chemotactic peptides, somatostatin analogs,
and selectin binding peptides;

d' is 1 to 3;

L_n is:

$-(CR^{55}R^{56})_{g''}-[Y^1(CR^{55}R^{56})_fY^2]_{f'}-(CR^{55}R^{56})_{g''}-$,

wherein:

g'' is 0-5;

f is 0-5;

f' is 1-5;

Y^1 and Y^2 , at each occurrence, are
independently selected from:

O, NR^{56} , C=O, C(=O)O, OC(=O)O,
C(=O)NH, C=NR⁵⁶, S, SO, SO₂, SO₃,
NHC(=O), (NH)₂C(=O), (NH)₂C=S;

R⁵⁵ and R⁵⁶ are independently selected at each occurrence from:

5

hydrogen; C₁-C₁₀ alkyl and alkaryl;

10 R⁴⁰ is independently selected at each occurrence from the group: aryl substituted with 0-3 R⁵², and heterocycle substituted with 0-3 R⁵²;

15 R⁴¹ is independently selected from the group: hydrogen, aryl substituted with 0-1 R⁵², C₁-C₃ alkyl substituted with 0-1 R⁵², and a heterocycle substituted with 0-1 R⁵²;

20

R⁵² is independently selected at each occurrence from the group: a bond to L_n, -CO₂R⁵³, -CH₂OR⁵³, -SO₃H, -SO₂R^{53a}, -N(R⁵³)₂, -N(R⁵³)₃⁺, -NHC(=NH)NHR⁵³, and -OCH₂CO₂H;

25

R⁵³ and R^{53a} are each independently selected at each occurrence from the group: hydrogen and C₁-C₃ alkyl;

30


R⁸⁰ is independently selected at each occurrence from the group: -CO₂R⁸⁵, C₂ - C₅ 1-alkene substituted with 0-3 R⁸⁴, C₂ - C₅ 1-alkyne substituted with 0-3 R⁸⁴.

35

aryl substituted with 0-3 R^{84} , and
unsaturated heterocycle substituted
with 0-3 R^{84} ;

5 R^{81} is independently selected at each
occurrence from the group: H and C_1 -
 C_5 alkyl;

10 or, alternatively, R^{80} and R^{81} , may be
taken together with the shown
divalent carbon radical to form:



15 wherein:

R^{82} and R^{83} may be independently
selected from the group:
H and R^{84} ;

20

or, alternatively, R^{82} , R^{83} may be
taken together to form a fused
aromatic or heterocyclic ring;

25

R^{84} is independently selected
at each occurrence from
the group: $-CO_2R^{85}$,
30 $-C(=O)N(R^{85})_2$, $-CH_2OR^{85}$,
 $-OC(=O)R^{85}$, $-OR^{85}$,
 $-SO_3H$, $-N(R^{85})_2$, and
 $-OCH_2CO_2H$;

30

R⁸⁵ is independently selected
at each occurrence from
the group: hydrogen and
C₁-C₃ alkyl.

5

Y is BR⁶⁴-;

R⁶⁴ is independently selected at each
occurrence from the group:

10

H, C₁-C₃ alkyl substituted with
0-3 R⁶⁵, aryl substituted with
0-3 R⁶⁵ and R⁶⁵;

15

or, alternatively, two R⁶⁴ may be
taken together with the atom
or atoms to which they are
attached to form a fused
aromatic, or heterocyclic
ring, substituted with 0-3 R⁶⁵;

20

R⁶⁵ is independently selected
at each occurrence from
the group: -NO₂,
-CO₂R⁶⁶, -OR⁶⁶, -SO₃H,
and -OCH₂CO₂H;

25

R⁶⁶ is hydrogen; and

30

n is 0.

[13] Also preferred are those kits wherein:

AL₁ is a tricine;

Q is a biologically active molecule selected from the group: IIb/IIIa receptor antagonists, and chemotactic peptides;

5

d' is 1;

Y¹ and Y², at each occurrence, are independently selected from:

10

O, NR⁵⁶, C=O, C(=O)O, OC(=O)O, C(=O)NH, C=NR⁵⁶, NHC(=O), (NH)₂C(=O);

15

R⁵⁵ and R⁵⁶ are hydrogen;

R⁴⁰ is heterocycle substituted with R⁵²;

20

R⁴¹ is hydrogen;

R⁵² is a bond to L_n;

25

R⁸⁰ is independently selected at each occurrence from the group:
-CO₂R⁸⁵, C₂ - C₃ 1-alkene substituted with 0-1 R⁸⁴, aryl substituted with 0-1 R⁸⁴, and unsaturated heterocycle substituted with 0-1 R⁸⁴;

30

R⁸¹ is H;

35

R⁸⁴ is independently selected at each occurrence from the group: -CO₂R⁸⁵, -OR⁸⁵, -SO₃H, and -N(R⁸⁵)₂;



- 5 R^{85} is independently selected at
 each occurrence from the
 group: hydrogen and methyl;
- 10 X^1 is independently selected at each
 occurrence from the group: CR^{64} and
 N;
- X^2 is independently selected at each
 occurrence from the group: CR^{64} ,
 $CR^{64}R^{64}$, N, NR^{64} , and O;
- 15 X^3 is N;
- Y is BR^{64-} ;
- 20 provided the total number of heteroatoms
 in each ring of the ligand A_{L2} is 2
 to 3;
- 25 R^{64} is independently selected at each
 occurrence from the group:
- H, C_1-C_3 alkyl substituted with
 0-1 R^{65} , aryl substituted with
 0-1 R^{65} , and R^{65} ;
- 30 R^{65} is independently selected at
 each occurrence from the
 group: $-NO_2$, $-CO_2R^{66}$,
 $-OR^{66}$, and $-SO_3H$;
- 35 R^{66} is hydrogen;
- n is 0;

and a, b, c, d, e and f indicate the positions of optional double bonds, provided that one of e and f is a double bond.





5

10 [14] Also preferred are those kits wherein:



AL2 is selected from the group:




15




20






Q is



d' is 1;

L_n is attached to Q at the carbon atom designated with a * and has the formula:



C_h is selected from $R^{40}NNH_2-$ and $R^{40}R^{41}N=N=CR^{80}R^{81}$, wherein,

R^{40} is independently selected at each occurrence from the group: heterocycle substituted with R^{52} ;

R⁴¹ is hydrogen;

R⁵² is a bond to L_n;

5 R⁸⁰ is independently selected at each
occurrence from the group:
-CO₂R⁸⁵, C₂ - C₃ 1-alkene
substituted with 0-1 R⁸⁴, aryl
substituted with 0-1 R⁸⁴ and
10 unsaturated heterocycle substituted
with 0-1 R⁸⁴;

R⁸¹ is H;

15 R⁸⁴ is independently selected at
each occurrence from the
group: -CO₂R⁸⁵, -OR⁸⁵,
-SO₃H, and -N(R⁸⁵)₂;

20 R⁸⁵ is independently selected at
each occurrence from the
group: hydrogen and methyl.

25 When any variable occurs more than one time in any
constituent or in any formula, its definition on each
occurrence is independent of its definition at every
other occurrence. Thus, for example, if a group is
shown to be substituted with 0-2 R⁵², then said group
30 may optionally be substituted with up to two R⁵² and R⁵²
at each occurrence is selected independently from the
defined list of possible R⁵². Also, by way of example,
for the group -N(R⁵³)₂, each of the two R⁵³ substituents
on N is independently selected from the defined list of
35 possible R⁵³. Combinations of substituents and/or
variables are permissible only if such combinations
result in stable compounds.

By "stable compound" or "stable structure" is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious diagnostic agent.

The term "capable of stabilizing", as used herein to describe the second ancillary ligand A_{L2} , means that the ligand is capable of coordinating to the transition metal radionuclide in the presence of the first ancillary ligand and the transition metal chelator, under the conditions specified herein, resulting in a radiopharmaceutical of Formula 1 having a minimal number of isomeric forms, the relative ratios of which do not change significantly with time, and that remains substantially intact upon dilution.

The term "substituted", as used herein, means that one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's or group's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.

The term "bond", as used herein, means either a single or double bond.

The term "salt", as used herein, is used as defined in the CRC Handbook of Chemistry and Physics, 65th Edition, CRC Press, Boca Raton, Fla, 1984, as any substance which yields ions, other than hydrogen or hydroxyl ions.

As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; "cycloalkyl" or "carbocycle" is intended to include saturated and partially unsaturated ring groups, including mono-, bi- or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and adamantyl; "bicycloalkyl" is intended to include saturated bicyclic ring groups such as [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, and so forth.

As used herein, the term "alkene" or "alkenyl" is intended to include both branched and straight-chain groups of the formula C_nH_{2n-1} having the specified number of carbon atoms.

As used herein, the term "alkyne" or "alkynyl" is intended to include both branched and straight-chain groups of the formula C_nH_{2n-3} having the specified number of carbon atoms.

As used herein, "aryl" or "aromatic residue" is intended to mean phenyl or naphthyl, which when substituted, the substitution can be at any position.

As used herein, the term "heterocycle" or "heterocyclic ring system" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring which may be saturated, partially unsaturated, or aromatic, and which consists of carbon atoms and from 1 to 4 heteroatoms selected independently from the group consisting of N, O and S and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen may optionally be quaternized, and including any bicyclic

group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The

5 heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. Examples of such heterocycles include, but are not limited to, benzopyranyl, thiadiazine, tetrazolyl, benzofuranyl, benzothiophenyl,

10 indolene, quinoline, isoquinoliny1 or benzimidazolyl, piperidinyl, 4-piperidone, 2-pyrrolidone, tetrahydrofuran, tetrahydroquinoline, tetrahydroisoquinoline, decahydroquinoline, octahydroisoquinoline, azocine, triazine (including

15 1,2,3-, 1,2,4-, and 1,3,5-triazine), 6H-1,2,5-thiadiazine, 2H,6H-1,5,2-dithiazine, thiophene, tetrahydrothiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, 2H-pyrrole, pyrrole, imidazole, pyrazole, thiazole,

20 isothiazole, oxazole (including 1,2,4- and 1,3,4-oxazole), isoxazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, 3H-indole, indole, 1H-indazole, purine, 4H-quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine,

25 quinoxaline, quinazoline, cinnoline, pteridine, 4aH-carbazole, carbazole, β -carboline, phenanthridine, acridine, perimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, isochroman, chroman, pyrrolidine, pyrroline,

30 imidazolidine, imidazoline, pyrazolidine, pyrazoline, piperazine, indoline, isoindoline, quinuclidine, or morpholine. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

35

As used herein, the term "alkaryl" means an aryl group bearing an alkyl group of 1-10 carbon atoms; the

term "aralkyl" means an alkyl group of 1-10 carbon atoms bearing an aryl group; the term "arylalkaryl" means an aryl group bearing an alkyl group of 1-10 carbon atoms bearing an aryl group; and the term "heterocycloalkyl" means an alkyl group of 1-10 carbon atoms bearing a heterocycle.

A "reducing agent" is a compound that reacts with the radionuclide, which is typically obtained as a relatively unreactive, high oxidation state compound, to lower its oxidation state by transferring electron(s) to the radionuclide, thereby making it more reactive. Reducing agents useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to stannous chloride, stannous fluoride, formamidine sulfinic acid, ascorbic acid, cysteine, phosphines, and cuprous or ferrous salts. Other reducing agents are described in Brodack et. al., PCT Application 94/22496, which is incorporated herein by reference.

A "transfer ligand" is a ligand that forms an intermediate complex with the radionuclide that is stable enough to prevent unwanted side-reactions but labile enough to be converted to the radiopharmaceutical. The formation of the intermediate complex is kinetically favored while the formation of the radiopharmaceutical is thermodynamically favored. Transfer ligands useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to gluconate, glucoheptonate, mannitol, glucarate, N,N,N',N'-ethylenediaminetetraacetic acid, pyrophosphate and methylenediphosphonate. In general, transfer ligands are comprised of oxygen or nitrogen donor atoms.

The term "donor atom" refers to the atom directly attached to a metal by a chemical bond.

"Ancillary" or "co-ligands" are ligands that are
5 incorporated into the radiopharmaceutical during its
synthesis. They serve to complete the coordination
sphere of the radionuclide together with the chelator or
radionuclide bonding unit of the reagent. For
radiopharmaceuticals comprised of a binary ligand
10 system, the radionuclide coordination sphere is composed
of one or more chelators or bonding units from one or
more reagents and one or more ancillary or co-ligands,
provided that there are a total of two types of ligands,
chelators or bonding units. For example, a
15 radiopharmaceutical comprised of one chelator or bonding
unit from one reagent and two of the same ancillary or
co-ligands and a radiopharmaceutical comprised of two
chelators or bonding units from one or two reagents and
one ancillary or co-ligand are both considered to be
20 comprised of binary ligand systems. For
radiopharmaceuticals comprised of a ternary ligand
system, the radionuclide coordination sphere is composed
of one or more chelators or bonding units from one or
more reagents and one or more of two different types of
25 ancillary or co-ligands, provided that there are a total
of three types of ligands, chelators or bonding units.
For example, a radiopharmaceutical comprised of one
chelator or bonding unit from one reagent and two
different ancillary or co-ligands is considered to be
30 comprised of a ternary ligand system.

Ancillary or co-ligands useful in the preparation
of radiopharmaceuticals and in diagnostic kits useful
for the preparation of said radiopharmaceuticals are
35 comprised of one or more oxygen, nitrogen, carbon,
sulfur, phosphorus, arsenic, selenium, and tellurium
donor atoms. A ligand can be a transfer ligand in the

synthesis of a radiopharmaceutical and also serve as an ancillary or co-ligand in another radiopharmaceutical. Whether a ligand is termed a transfer or ancillary or co-ligand depends on whether the ligand remains in the
5 radionuclide coordination sphere in the radiopharmaceutical, which is determined by the coordination chemistry of the radionuclide and the chelator or bonding unit of the reagent or reagents.

10 A "chelator" or "bonding unit" is the moiety or group on a reagent that binds to a metal radionuclide through the formation of chemical bonds with one or more donor atoms.

15 The term "binding site" means the site in vivo or in vitro that binds a biologically active molecule.

A "diagnostic kit" comprises a collection of components, termed the formulation, in one or more
20 vials which are used by the practising end user in a clinical or pharmacy setting to synthesize the radiopharmaceutical. The kit provides all the requisite components to synthesize and use the radiopharmaceutical except those that are commonly available to the
25 practising end user, such as water or saline for injection, a solution of the radionuclide, equipment for heating the kit during the synthesis of the radiopharmaceutical if required, equipment necessary for administering the radiopharmaceutical to the patient
30 such as syringes and shielding, and imaging equipment.

A "buffer" is a compound that is used to control the pH of the kit during its manufacture and during the synthesis of the radiopharmaceutical.
35

A "lyophilization aid" is a component that has favorable physical properties for lyophilization, such

as the glass transition temperature, and is added to the diagnostic kit to improve the physical properties of the combination of all the components of the kit for lyophilization.

5

A "stabilization aid" is a component that is added to the radiopharmaceutical or to the diagnostic kit either to stabilize the radiopharmaceutical once it is synthesized or to prolong the shelf-life of the kit before it must be used. Stabilization aids can be
10 antioxidants, reducing agents or radical scavengers and can provide improved stability by reacting preferentially with species that degrade other components or the radiopharmaceutical.

15

A "solubilization aid" is a component that improves the solubility of one or more other components in the medium required for the synthesis of the radiopharmaceutical.

20

A "bacteriostat" is a component that inhibits the growth of bacteria in the diagnostic kit either during its storage before use or after the kit is used to synthesize the radiopharmaceutical.

25

The radiopharmaceuticals of the present invention are of the formula $\{(Q)_{d'}L_n\text{-}Ch'\}_x\text{-}M_t(A_{L1})_y(A_{L2})_z$, wherein Q is a biologically active group, d' is an integer from 1 to 20, L_n is an optional linking group, Ch' is a
30 radionuclide metal chelator or bonding unit bound to the transition metal radionuclide, M_t , of the formulae $R^{40}N=N^+=$, $R^{40}R^{41}N=N=$, or $R^{40}N=N(H)-$, A_{L1} is a first ancillary or co-ligand, A_{L2} is a second ancillary or co-ligand, x, y and z are independently 1 or 2.

35

The biologically active molecule Q can be a protein, antibody, antibody fragment, peptide or

polypeptide, or peptidomimetic that is comprised of a recognition sequence or unit for a receptor or binding site expressed at the site of the disease, or for a receptor or binding site expressed on platelets or leukocytes. The exact chemical composition of Q is selected based on the disease state to be diagnosed, the mechanism of localization to be utilized, and to provide an optimum combination of rates of localization, clearance and radionuclidic decay.

For the purposes of this invention, the term thromboembolic disease is taken to include both venous and arterial disorders and pulmonary embolism, resulting from the formation of blood clots.

For the diagnosis of thromboembolic disorders or atherosclerosis, Q is selected from the group including the cyclic IIb/IIIa receptor antagonist compounds described in co-pending U.S. Ser. No.08/218,861 (equivalent to WO 94/22494); the RGD containing peptides described in U.S. Patents 4,578,079, 4,792,525, the applications PCT US88/04403, PCT US89/01742, PCT US90/03788, PCT US91/02356 and by Ojima et. al., 204th Meeting of the Amer. Chem. Soc., 1992, Abstract 44; the peptides that are fibrinogen receptor antagonists described in European Patent Applications 90202015.5, 90202030.4, 90202032.2, 90202032.0, 90311148.2, 90311151.6, 90311537.6, the specific binding peptides and polypeptides described as IIb/IIIa receptor ligands, ligands for the polymerization site of fibrin, laminin derivatives, ligands for fibrinogen, or thrombin ligands in PCT WO 93/23085 (excluding the technetium binding groups); the oligopeptides that correspond to the IIIa protein described in PCT WO90/00178; the hirudin-based peptides described in PCT WO90/03391; the IIb/IIIa receptor ligands described in PCT WO90/15818; the thrombus, platelet binding or atherosclerotic plaque

binding peptides described in PCT WO92/13572 (excluding the technetium binding group) or GB 9313965.7; the fibrin binding peptides described in U.S. Patents 4,427,646 and 5,270,030; the hirudin-based peptides described in U.S. Patent 5,279,812; or the fibrin binding proteins described in U.S. Patent 5,217,705; the guanine derivatives that bind to the IIb/IIIa receptor described in U.S. Patent 5,086,069; or the tyrosine derivatives described in European Patent Application 0478328A1, and by Hartman et. al., J. Med. Chem., 1992, 35, 4640; or oxidized low density lipoprotein (LDL).

For the diagnosis of infection, inflammation or transplant rejection, Q is selected from the group including the leukocyte binding peptides described in PCT WO93/17719 (excluding the technetium binding group), PCT WO92/13572 (excluding the technetium binding group) or U.S. Ser. No. 08/140000; the chemotactic peptides described in Eur. Pat. Appl. 90108734.6 or A. Fischman et. al., Semin. Nuc. Med., 1994, 24, 154; or the leukostimulatory agents described in U.S. Patent 5,277,892.

For the diagnosis of cancer, Q is selected from the group of somatostatin analogs described in UK Application 8927255.3 or PCT WO94/00489, the selectin binding peptides described in PCT WO94/05269, the biological-function domains described in PCT WO93/12819, Platelet Factor 4 or the growth factors (PDGF, EGF, FGF, TNF, MCSF or Il-8).

Q may also represent proteins, antibodies, antibody fragments, peptides, polypeptides, or peptidomimetics that bind to receptors or binding sites on other tissues, organs, enzymes or fluids. Examples include the β -amyloid proteins that have been demonstrated to accumulate in patients with Alzheimer's disease, atrial

naturetic factor derived peptides that bind to myocardial and renal receptors, antimyosin antibodies that bind to areas of infarcted tissues, or nitroimidazole derivatives that localize in hypoxic areas in vivo.

The group Ch is termed a hydrazido (of formula $R^{40}R^{41}N=N=$), or diazenido (of formula $R^{40}N=N+=$ or $R^{40}N=N(H)-$) group and serves as the point of attachment of the radionuclide to the remainder of the radiopharmaceutical designated by the formula $(Q)_d-L_n$ or $(Q)_d$. A diazenido group can be either terminal (only one atom of the group is bound to the radionuclide) or chelating. In order to have a chelating diazenido group at least one other atom of the group, located on R^{40} , must also be bound to the radionuclide. The atoms bound to the metal are termed donor atoms.

The transition metal radionuclide, M_t , is selected from the group: technetium-99m, rhenium-186 and rhenium-188. For diagnostic purposes Tc-99m is the preferred isotope. Its 6 hour half-life and 140 keV gamma ray emission energy are almost ideal for gamma scintigraphy using equipment and procedures well established for those skilled in the art. The rhenium isotopes also have gamma ray emission energies that are compatible with gamma scintigraphy, however, they also emit high energy beta particles that are more damaging to living tissues. These beta particle emissions can be utilized for therapeutic purposes, for example, cancer radiotherapy.

The coordination sphere of the radionuclide includes all the ligands or groups bound to the radionuclide. For a transition metal radionuclide, M_t , to be stable it typically has a coordination number

(number of donor atoms) comprised of an integer greater than or equal to 4 and less than or equal to 8; that is there are 4 to 8 atoms bound to the metal and it is said to have a complete coordination sphere. The requisite
5 coordination number for a stable radionuclide complex is determined by the identity of the radionuclide, its oxidation state, and the type of donor atoms. If the chelator or bonding unit C_n does not provide all of the atoms necessary to stabilize the metal radionuclide by
10 completing its coordination sphere, the coordination sphere is completed by donor atoms from other ligands, termed ancillary or co-ligands, which can also be either terminal or chelating.

15 A large number of ligands can serve as ancillary or co-ligands, the choice of which is determined by a variety of considerations such as the ease of synthesis of the radiopharmaceutical, the chemical and physical properties of the ancillary ligand, the rate of
20 formation, the yield, and the number of isomeric forms of the resulting radiopharmaceuticals, the ability to administer said ancillary or co-ligand to a patient without adverse physiological consequences to said patient, and the compatibility of the ligand in a
25 lyophilized kit formulation. The charge and lipophilicity of the ancillary ligand will effect the charge and lipophilicity of the radiopharmaceuticals. For example, the use of 4,5-dihydroxy-1,3-benzene disulfonate results in radiopharmaceuticals with an
30 additional two anionic groups because the sulfonate groups will be anionic under physiological conditions. The use of N-alkyl substituted 3,4-hydroxypyridinones results in radiopharmaceuticals with varying degrees of lipophilicity depending on the size of the alkyl
35 substituents.

The radiopharmaceuticals of the present invention are comprised of two types of ancillary or co-ligands designated AL_1 and AL_2 . Ancillary ligands AL_1 are comprised of two or more hard donor atoms such as oxygen and amine nitrogen (sp^3 hybridized). The donor atoms occupy at least two of the sites in the coordination sphere of the radionuclide metal, M_t ; the ancillary ligand AL_1 serves as one of the three ligands in the ternary ligand system. Examples of ancillary ligands AL_1 include but are not limited to dioxygen ligands and functionalized aminocarboxylates. A large number of such ligands are available from commercial sources.

Ancillary dioxygen ligands include ligands that coordinate to the metal ion through at least two oxygen donor atoms. Examples include but are not limited to: glucoheptonate, gluconate, 2-hydroxyisobutyrate, lactate, tartrate, mannitol, glucarate, maltol, Kojic acid, 2,2-bis(hydroxymethyl)propionic acid, 4,5-dihydroxy-1,3-benzene disulfonate, or substituted or unsubstituted 1,2 or 3,4 hydroxypyridinones. (The names for the ligands in these examples refer to either the protonated or non-protonated forms of the ligands.)

Functionalized aminocarboxylates include ligands that have a combination of amine nitrogen and oxygen donor atoms. Examples include but are not limited to: iminodiacetic acid, 2,3-diaminopropionic acid, nitrilotriacetic acid, N,N'-ethylenediamine diacetic acid, N,N,N'-ethylenediamine triacetic acid, hydroxyethylethylenediamine triacetic acid, and N,N'-ethylenediamine bis-hydroxyphenylglycine. (The names for the ligands in these examples refer to either the protonated or non-protonated forms of the ligands.)

A series of functionalized aminocarboxylates are disclosed by Bridger et. al. in U.S. Patent 5,350,837,

herein incorporated by reference, that result in improved rates of formation of technetium labeled hydrazino modified proteins. We have determined that certain of these aminocarboxylates result in improved
5 yields of the radiopharmaceuticals of the present invention. The preferred ancillary ligands A_{L1} functionalized aminocarboxylates that are derivatives of glycine; the most preferred is tricine (tris(hydroxymethyl)methylglycine).

10

The second type of ancillary ligands A_{L2} are comprised of one or more soft donor atoms selected from the group: imine nitrogen (sp^2 hybridized), sulfur (sp^2 hybridized) and carbon (sp hybridized); atoms which have
15 π -acid character. Ligands A_{L2} can be monodentate, bidentate or tridentate, the denticity is defined by the number of donor atoms in the ligand. One of the two donor atoms in a bidentate ligand and one of the three donor atoms in a tridentate ligand must be a soft donor
20 atom.

The ligands A_{L2} that are comprised of imine nitrogen are unsaturated or aromatic nitrogen-containing, 5 or 6-membered heterocycles. The ligands
25 that are comprised of sulfur (sp^2 hybridized) donor atoms are thiocarbonyls, comprised of the moiety $C=S$. The ligands comprised of carbon (sp hybridized) donor atoms are isonitriles, comprised of the moiety CNR , where R is an organic radical. A large number of such
30 ligands are available from commercial sources. Isonitriles can be synthesized as described in European Patent 0107734 and in U. S. Patent 5,279,811, herein incorporated by reference. Preferred ancillary
ligands A_{L2} are unsaturated or aromatic 5 or 6 membered
35 heterocycles. The most preferred ancillary ligands A_{L2} are unsaturated 5 membered heterocycles.

The ancillary ligands AL_2 may be substituted with alkyl, aryl, alkoxy, heterocycle, aralkyl, alkaryl and arylalkaryl groups and may or may not bear functional groups comprised of heteroatoms such as oxygen, nitrogen, phosphorus or sulfur. Examples of such functional groups include but are not limited to: hydroxyl, carboxyl, carboxamide, nitro, ether, ketone, amino, ammonium, sulfonate, sulfonamide, phosphonate, and phosphonamide. The functional groups may be chosen to alter the lipophilicity and water solubility of the ligands which may affect the biological properties of the radiopharmaceuticals, such as altering the distribution into non-target tissues, cells or fluids, and the mechanism and rate of elimination from the body.

The radiopharmaceuticals of the present invention can be easily prepared by admixing a salt of a radionuclide, a reagent of Formula 2, an ancillary ligand AL_1 , an ancillary ligand AL_2 , and a reducing agent, in an aqueous solution at temperatures from room temperature to 100 °C.



and pharmaceutically acceptable salts thereof, wherein: Q, d', L_n are as defined above, C_h is a radionuclide metal chelator selected from the group: $R^{40}R^{41}N=N=C(C_1-C_3 \text{ alkyl})_2$ and $R^{40}NNH_2-$, and $R^{40}R^{41}N=N=C(R^{80})(R^{81})$, and pharmaceutically acceptable salts thereof. The synthesis of reagents of formula 2 is described in co-pending U.S.S.N. 08/218,861 (equivalent to WO 94/22494) and in co-pending U.S.S.N. 08/476,296.

When C_h is a hydrazone group, then it must first be converted to a hydrazine of formula $R^{40}R^{41}NNH_2$, which may or may not be protonated, prior to complexation

with the metal radionuclide, M_t . The chelator or bonding unit, C_h , when bound to the metal radionuclide, M_t , is designated C_h' . The conversion of the hydrazone group to the hydrazine can occur either prior to reaction with the radionuclide, in which case the radionuclide and the ancillary or co-ligand or ligands are combined not with the reagent but with a hydrolyzed form of the reagent bearing the chelator or bonding unit, C_h , or in the presence of the radionuclide in which case the reagent itself is combined with the radionuclide and the ancillary or co-ligand or ligands. In the latter case, the pH of the reaction mixture must be neutral or acidic.

Alternatively, the radiopharmaceuticals of the present invention can be prepared by first admixing a salt of a radionuclide, an ancillary ligand A_{L1} , and a reducing agent in an aqueous solution at temperatures from room temperature to 100 °C to form an intermediate radionuclide complex with the ancillary ligand A_{L1} then adding a reagent of Formula 2 and an ancillary ligand A_{L2} and reacting further at temperatures from room temperature to 100 °C.

Alternatively, the radiopharmaceuticals of the present invention can be prepared by first admixing a salt of a radionuclide, an ancillary ligand A_{L1} , a reagent of Formula 2, and a reducing agent in an aqueous solution at temperatures from room temperature to 100 °C to form an intermediate radionuclide complex, and then adding an ancillary ligand A_{L2} and reacting further at temperatures from room temperature to 100 °C.

The total time of preparation will vary depending on the identity of the radionuclide, the identities and amounts of the reactants and the procedure used for the preparation. The preparations may be complete, resulting

in > 80% yield of the radiopharmaceutical, in 1 minute or may require more time. If higher purity radiopharmaceuticals are needed or desired, the products can be purified by any of a number of techniques well known to those skilled in the art such as liquid chromatography, solid phase extraction, solvent extraction, dialysis or ultrafiltration.

The technetium and rhenium radionuclides are preferably in the chemical form of pertechnetate or perrhenate and a pharmaceutically acceptable cation. The pertechnetate salt form is preferably sodium pertechnetate such as obtained from commercial Tc-99m generators. The amount of pertechnetate used to prepare the radiopharmaceuticals of the present invention can range from 0.1 mCi to 1 Ci, or more preferably from 1 to 200 mCi.

The amount of the reagent of formula 2 used to prepare the radiopharmaceuticals of the present invention can range from 0.1 μ g to 10 mg, or more preferably from 0.5 μ g to 100 μ g. The amount used will be dictated by the amounts of the other reactants and the identity of the radiopharmaceuticals of Formula 1 to be prepared.

The amounts of the ancillary ligands A_{L1} used can range from 0.1 mg to 1 g, or more preferably from 1 mg to 100 mg. The exact amount for a particular radiopharmaceutical is a function of identity of the radiopharmaceuticals of Formula 1 to be prepared, the procedure used and the amounts and identities of the other reactants. Too large an amount of A_{L1} will result in the formation of by-products comprised of technetium labeled A_{L1} without a biologically active molecule or by-products comprised of technetium labeled biologically active molecules with the ancillary ligand A_{L1} but

without the ancillary ligand A_{L2} . Too small an amount of A_{L1} will result in other by-products such as technetium labeled biologically active molecules with the ancillary ligand A_{L2} but without the ancillary ligand A_{L1} , or
5 reduced hydrolyzed technetium, or technetium colloid.

The amounts of the ancillary ligands A_{L2} used can range from 0.001 mg to 1 g, or more preferably from 0.01 mg to 10 mg. The exact amount for a particular
10 radiopharmaceutical is a function of the identity of the radiopharmaceuticals of Formula 1 to be prepared, the procedure used and the amounts and identities of the other reactants. Too large an amount of A_{L2} will result in the formation of by-products comprised of technetium
15 labeled A_{L2} without a biologically active molecule or by-products comprised of technetium labeled biologically active molecules with the ancillary ligand A_{L2} but without the ancillary ligand A_{L1} . If the moiety $(Q)_{d'}-L_n-CH$ bears one or more substituents that are comprised
20 of a soft donor atom, as defined above, at least a ten-fold molar excess of the ancillary ligand A_{L2} to the reagent of formula 2 is required to prevent the substituent from interfering with the coordination of the ancillary ligand A_{L2} to the metal radionuclide, M_t .

25

Suitable reducing agents for the synthesis of the radiopharmaceuticals of the present invention include stannous salts, dithionite or bisulfite salts, borohydride salts, and formamidinesulfinic acid, wherein
30 the salts are of any pharmaceutically acceptable form. The preferred reducing agent is a stannous salt. The amount of a reducing agent used can range from 0.001 mg to 10 mg, or more preferably from 0.005 mg to 1 mg.

35

The specific structure of a radiopharmaceutical of the present invention will depend on the identity of the biologically active molecule Q , the number d' , the

identity of the linker L_n , the identity of the chelator moiety Ch' , the identity of the ancillary ligand A_{L1} , the identity of the ancillary ligand A_{L2} , and the identity of the radionuclide M_t . The identities of Q , L_n , and Ch' and the number d' are determined by the choice of the reagent of Formulae 2 or 3. For a given reagent of Formulae 2 or 3, the amount of the reagent, the amount and identity of the ancillary ligands A_{L1} and A_{L2} , the identity of the radionuclide M_t and the synthesis conditions employed will determine the structure of the radiopharmaceutical of Formula 1.

Radiopharmaceuticals synthesized using concentrations of reagents of Formulae 2 or 3 of $<100 \mu\text{g/mL}$, will be comprised of one hydrazido or diazenido group Ch' ; the value of x will be 1. Those synthesized using $>1 \text{ mg/mL}$ concentrations will be comprised of two hydrazido or diazenido groups; the value of x will be 2. The two Ch' groups may be the same or different. For most applications, only a limited amount of the biologically active molecule can be injected and not result in undesired side-effects, such as chemical toxicity, interference with a biological process or an altered biodistribution of the radiopharmaceutical. Therefore, the radiopharmaceuticals with x equal to 2, which require higher concentrations of the reagents of Formula 2 comprised in part of the biologically active molecule, will have to be diluted or purified after synthesis to avoid such side-effects.

The identities and amounts used of the ancillary ligands A_{L1} and A_{L2} will determine the values of the variables y and z . The values of y and z can independently be an integer from 1 to 2. In combination, the values of y and z will result in a technetium coordination sphere that is made up of at least five and no more than seven donor atoms. For

monodentate ancillary ligands A_{L2} , z can be an integer from 1 to 2; for bidentate or tridentate ancillary ligands A_{L2} , z is 1. The preferred combination for monodentate ligands is y equal to 1 or 2 and z equal to 1. The preferred combination for bidentate or tridentate ligands is y equal to 1 and z equal to 1.

Another aspect of the present invention are diagnostic kits for the preparation of radiopharmaceuticals useful as imaging agents for the diagnosis of cardiovascular disorders, infectious disease, inflammatory disease and cancer. Diagnostic kits of the present invention comprise one or more vials containing the sterile, non-pyrogenic, formulation comprised of a predetermined amount of the reagent of formulae $(Q)_{d'}-L_n-C_h$ or $(Q)_{d'}-L_n-H_z$, one or two ancillary or co-ligands and optionally other components such as reducing agents, transfer ligands, buffers, lyophilization aids, stabilization aids, solubilization aids and bacteriostats. The inclusion of one or more optional components in the formulation will frequently improve the ease of synthesis of the radiopharmaceutical by the practising end user, the ease of manufacturing the kit, the shelf-life of the kit, or the stability and shelf-life of the radiopharmaceutical. The improvement achieved by the inclusion of an optional component in the formulation must be weighed against the added complexity of the formulation and added cost to manufacture the kit. The one or more vials that contain all or part of the formulation can independently be in the form of a sterile solution or a lyophilized solid.

Buffers useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to phosphate, citrate, sulfosalicylate,

and acetate. A more complete list can be found in the United States Pharmacopeia.

5 Lyophilization aids useful in the preparation of diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to mannitol, lactose, sorbitol, dextran, Ficoll, and polyvinylpyrrolidone (PVP).

10 Stabilization aids useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to ascorbic acid, cysteine, monothioglycerol, sodium bisulfite, sodium
15 metabisulfite, gentisic acid, and inositol.

20 Solubilization aids useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to ethanol, glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monooleate, polysorbates, poly(oxyethylene)poly(oxypropylene)poly(oxyethylene)
25 block copolymers (Pluronic) and lecithin. Preferred solubilizing aids are polyethylene glycol, and Pluronic.

30 Bacteriostats useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to benzyl alcohol, benzalkonium chloride, chlorbutanol, and methyl, propyl or butyl paraben.

35 A component in a diagnostic kit can also serve more than one function. A reducing agent can also serve as a stabilization aid, a buffer can also serve as a transfer

ligand, a lyophilization aid can also serve as a transfer, ancillary or co-ligand and so forth.

5 The predetermined amounts of each component in the formulation are determined by a variety of considerations that are in some cases specific for that component and in other cases dependent on the amount of another component or the presence and amount of an optional component. In general, the minimal amount of
10 each component is used that will give the desired effect of the formulation. The desired effect of the formulation is that the practising end user can synthesize the radiopharmaceutical and have a high degree of certainty that the radiopharmaceutical can be
15 safely injected into a patient and will provide diagnostic information about the disease state of that patient.

20 The diagnostic kits of the present invention will also contain written instructions for the practising end user to follow to synthesize the radiopharmaceuticals. These instructions may be affixed to one or more of the vials or to the container in which the vial or vials are packaged for shipping or may be a separate insert,
25 termed the package insert.

Another aspect of the present invention contemplates a method of imaging the site of thrombotic disease in a patient involving: (1) synthesizing a
30 radiopharmaceutical using a reagent of the present invention capable of localizing at sites of thrombotic disease due to an interaction between the biologically active group, Q, of the radiopharmaceutical and a receptor or binding site expressed at the site of the
35 disease or with a receptor or binding site on an endogenous blood component that accumulates at the site; (2) administering said radiopharmaceutical to a patient

by injection or infusion; (3) imaging the patient using either planar or SPECT gamma scintigraphy.

Another aspect of the present invention
5 contemplates a method of imaging the site of infection or infectious disease in a patient involving: (1) synthesizing a radiopharmaceutical using a reagent of the present invention capable of localizing at sites of infection or infectious disease due to an interaction
10 between the biologically active group, Q, of the radiopharmaceutical and a receptor or binding site expressed at the site of the disease or with a receptor or binding site on an endogenous blood component that accumulates at the site; (2) administering said
15 radiopharmaceutical to a patient by injection or infusion; (3) imaging the patient using either planar or SPECT gamma scintigraphy.

Another aspect of the present invention
20 contemplates a method of imaging the site of inflammation in a patient involving: (1) synthesizing a radiopharmaceutical using a reagent of the present invention capable of localizing at sites of inflammation due to an interaction between the biologically active
25 group, Q, of the radiopharmaceutical and a receptor or binding site expressed at the site of inflammation or with a receptor or binding site on an endogenous blood component that accumulates at the site; (2) administering said radiopharmaceutical to a patient by
30 injection or infusion; (3) imaging the patient using either planar or SPECT gamma scintigraphy.

Another aspect of the present invention
contemplates a method of imaging the site of cancer in a
35 patient involving: (1) synthesizing a radiopharmaceutical using a reagent of the present invention capable of localizing at sites of cancer due

to an interaction between the biologically active group, Q, of the radiopharmaceutical and a receptor or binding site expressed at the site of the cancer or with a receptor or binding site on an endogenous blood component that accumulates at the site; (2) administering said radiopharmaceutical to a patient by injection or infusion; (3) imaging the patient using either planar or SPECT gamma scintigraphy.

The radiopharmaceuticals are administered by intravenous injection, usually in saline solution, at a dose of 1 to 100 mCi per 70 kg body weight, or preferably at a dose of 5 to 50 mCi. Imaging is performed using known procedures.

15

EXAMPLE SECTION

The materials used to synthesize the radiopharmaceuticals of the present invention described in the following examples were obtained as follows. The reagent of Formula 2, Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) was synthesized as described in co-pending U.S. Ser. No. 08/218,861 (equivalent to WO 94/22494). The ancillary ligands tricine, tris(1-pyrazoyl)borohydride, imidazole, 2-methyl-5-nitroimidazole, ornidazole, metronidazole, 1,2,4-triazole, 3-nitro-1,2,4-triazole, acetyl histamine, urocanic acid, 2-methylimidazoline, 4-methyl-5-thiazoleethanol, tris(3,5-dimethyl-1-pyrazolyl)borohydride, adenosine, 8-hydroxyquinoline-5-sulfonic acid, and stannous chloride were obtained from commercial sources and used as received. Deionized water was obtained from a Milli-Q Water System and was of > 18 M Ω quality. Technetium-99m-pertechnetate ($^{99m}\text{TcO}_4^-$) was obtained from a DuPont Pharma $^{99}\text{Mo}/^{99m}\text{Tc}$ generator.

Example 1.

Synthesis of $^{99m}\text{Tc}(\text{tricine})(\text{tris}(1\text{-pyrazolyl})\text{borohydride})\text{-Cyclo}(\text{D-Val-NMeArg-Gly-Asp-Mamb}(\text{hydrazino-nicotinyl-5-Aca}))$

To a 10 mL vial was added 0.4 mL of $^{99m}\text{TcO}_4^-$ (100 mCi/mL) eluent, followed by 0.1 mL of Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) (100 $\mu\text{g/mL}$) in saline, 0.3 mL of tricine (100 mg/mL, pH 7), and 10 μL of SnCl_2 (10 mg/mL) in 1N HCl. The reaction mixture was heated at 50 $^\circ\text{C}$ for 15 min. To the reaction solution above was added 0.25 mL of tris(1-pyrazolyl)borohydride (20 mg/mL) in saline. The mixture was heated at 50 $^\circ\text{C}$ for 30 min, and was then analyzed by HPLC Method 1.

15

Example 2

Synthesis of $^{99m}\text{Tc}(\text{tricine})(\text{imidazole})\text{-Cyclo}(\text{D-Val-NMeArg-Gly-Asp-Mamb}(\text{hydrazino-nicotinyl-5-Aca}))$

To a 10 mL vial was added 0.3 mL of $^{99m}\text{TcO}_4^-$ solution (100 mCi/mL) in saline, 0.4 mL of tricine solution (100 mg/mL, pH ~ 5.0) in H_2O , 0.1 mL of Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) solution (100 $\mu\text{g/mL}$) in H_2O , and 10 μL of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ solution (10 mg/mL) in 1.0 N HCl. The reaction mixture was allowed to stand at room temperature for 15 min. After addition of 0.4 mL of imidazole solution (10 mg/mL) in H_2O , the reaction mixture was heated at 70 $^\circ\text{C}$ for 30 min, and was then analyzed by HPLC Method 1.

Example 3.

30 Synthesis of $^{99m}\text{Tc}(\text{tricine})(1,2,4\text{-triazole})\text{-Cyclo}(\text{D-Val-NMeArg-Gly-Asp-Mamb}(\text{hydrazino-nicotinyl-5-Aca}))$

To a 10 mL vial was added 0.3 mL of $^{99m}\text{TcO}_4^-$ solution (100 mCi/mL) in saline, 0.4 mL of tricine solution (100 mg/mL, pH ~ 5.0) in H_2O , 0.2 mL of Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) solution (50 $\mu\text{g/mL}$) in H_2O , 0.2 mL of 3-nitro-1,2,4-triazole solution (30 mg/mL) in H_2O , and 5 μL of

Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) solution (50 µg/mL) in H₂O, and 10 µL of SnCl₂·2H₂O solution (10 mg/mL) in 1.0 N HCl. The reaction mixture was heated at 50 °C for 30 min. After addition of 0.5 mL of metronidazole solution (20 mg/mL) in H₂O, the reaction mixture was heated at 70 °C for 30 min, and was then analyzed by HPLC Method 1.

Example 7.

10 Synthesis of ^{99m}Tc(tricine)(2-methylimidazoline)-Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca))

To a 10 mL vial was added 0.4 mL of ^{99m}TcO₄⁻ (100 mCi/mL) eluent, followed by 0.2 mL of Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) (50 µg/mL) in saline, 0.3 mL of tricine (100 mg/mL, pH 7), and 10 µL of SnCl₂ (10 mg/mL) in 1N HCl. The reaction mixture was heated at 50 °C for 15 min. To the reaction solution above was added 0.5 mL of 2-methylimidazoline (20 mg/mL) in saline. The mixture was heated at 55 °C for 60 min, and was then analyzed by HPLC Method 1.

Example 8.

25 Synthesis of ^{99m}Tc(tricine)(3-pyridinesulfonic acid)(Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca))

To a 10 mL vial was added 0.4 mL of tricine solution (100 mg/mL, pH 5.0) in H₂O, 0.4 mL of Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) solution (50 µg/mL) in H₂O, 0.2 mL of 3-pyridinesulfonic acid solution (10 mg/mL) in H₂O, 0.3 mL of ^{99m}TcO₄⁻ solution (100 mCi/mL) in saline, and 25 µL of SnCl₂·2H₂O solution (10 mg/mL) in 0.1 N HCl. The mixture was heated at 80 °C for 20 min, and was then analyzed by HPLC Method 2.

Example 9.

Synthesis of ^{99m}Tc (tricine)(4-methyl-5-thiazoleethanol)-Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca))

- 5 To a 10 mL vial was added 0.4 mL of $^{99m}\text{TcO}_4^-$ (100 mCi/mL) eluent, followed by 0.2 mL of Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) (50 $\mu\text{g/mL}$) in saline, 0.3 mL of tricine (100 mg/mL, pH 7), and 10 μL of SnCl_2 (10 mg/mL) in 1N HCl. The reaction
10 mixture was heated at 50 $^\circ\text{C}$ for 30 min. To the reaction solution above was added 0.5 mL of 4-methylthiazoleethanol (10 mg/mL) in in saline. The mixture was heated at 75 $^\circ\text{C}$ for 30 min, and was then analyzed by HPLC Method 1.

15

Example 10.

Synthesis of ^{99m}Tc (tricine)(tris(3,5-dimethylpyrazolyl)borohydride)-Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca))

- 20 To a 10 mL vial was added 0.2 mL of $^{99m}\text{TcO}_4^-$ (100 mCi/mL) eluent, followed by 0.2 mL of Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) (50 $\mu\text{g/mL}$) in saline, 0.4 mL of tricine (100 mg/mL, pH 7), 0.2 mL of tris(3,5-dimethylpyrazolyl)borohydride (20
25 mg/mL) in saline, and 10 μL of SnCl_2 (10 mg/mL) in 1N HCl. The mixture was heated at 75 $^\circ\text{C}$ for 30 min, and was then analyzed by HPLC Method 1.

Example 11.

- 30 Synthesis of ^{99m}Tc (tricine)(4-pyridineethanesulfonic acid)(Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca))

- To a 10 mL vial was added 0.4 mL of tricine solution (100 mg/mL, pH 5.0) in H_2O , 0.4 mL of Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) (50
35 $\mu\text{g/mL}$) in H_2O , 0.4 mL of 4-pyridineethanesulfonic acid solution (35 mg/mL) in H_2O , 0.2 mL of $^{99m}\text{TcO}_4^-$ solution

(250 mCi/mL) in saline, and 25 μ L of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ solution (10 mg/mL) in 0.1 N HCl. The reaction mixture was heated at 80 °C for 20 min, and was then analyzed by HPLC Method 1.

5

Example 12.

Synthesis of $^{99\text{m}}\text{Tc}$ (tricine)(ornidazole)-Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca))

10 To a 10 mL vial was added 0.4 mL of $^{99\text{m}}\text{TcO}_4^-$ solution (100 mCi/mL) in saline, 0.2 mL of tricine solution (100 mg/mL, pH ~ 5.0) in H_2O , 0.2 mL of Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) solution (50 μ g/mL) in H_2O , and 10 μ L of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ solution (10 mg/mL) in 1.0 N HCl. The reaction mixture was allowed to stand at room temperature for 20 min. After addition of 0.5 mL of ornidazole solution (20 mg/mL) in H_2O , the reaction mixture was heated at 70 °C for 30 min, and was then analyzed by HPLC Method 1.

20

Example 13.

Synthesis of $^{99\text{m}}\text{Tc}$ (tricine)(4-(3H)pyrimidone)(Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca))

To a 10 mL vial was added 0.4 mL of tricine solution (100 mg/mL, pH 5.0) in H_2O , 0.4 mL of Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca)) (50 μ g/mL) in H_2O , 0.2 mL of 4-(3H)pyrimidone solution (10 mg/mL) in H_2O , 0.3 mL of $^{99\text{m}}\text{TcO}_4^-$ solution (100 mCi/mL) in saline, and 25 μ L of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ solution (10 mg/mL) in 0.1 N HCl. The reaction mixture was heated at 80 °C for 20 min, and was then analyzed by HPLC Method 2.

25

30

Example 14.

Synthesis of $^{99\text{m}}\text{Tc}$ (tricine)(2-methyl-5-nitroimidazole)-Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-Aca))

35

To a 10 mL vial was added 0.4 mL of $^{99m}\text{TcO}_4^-$ solution (100 mCi/mL) in saline, 0.2 mL of tricine solution (100 mg/mL, pH ~ 5.0) in H_2O , 0.2 mL of Cyclo(D-Val-NMeArg-Gly-Asp-Mamb(hydrazino-nicotinyl-5-
5 Aca)) solution (50 $\mu\text{g/mL}$) in H_2O , and 10 μL of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ solution (10 mg/mL) in 1.0 N HCl. The reaction mixture was allowed to stand at room temperature for 15 min. After addition of 0.2 mL of 2-methyl-5-nitroimidazole solution (10 mg/mL) in H_2O , the reaction mixture was
10 heated at 70 $^\circ\text{C}$ for 30 min, and was then analyzed by HPLC Method 1.

Table 1
Analytical and Yield Data on Ternary Complexes

<u>Example</u>	<u>Retention Time</u> (min)	<u>% Yield</u>
1	11.8	91
2	12.1, 12.5	86
3	12.7, 12.9	99
4	13.0, 13.2	95
5	12.6	97
6	14.4	89
7	12.3	97
8	8.8*	91
9	13.4	92
10	14.9, 15.5	89
11	12.4	90
12	16.0, 16.5	81
13	8.1, 8.5*	89
14	12.8	71

* Data from Method 2; the others are from Method 1.

- 5 The values reported in Table 1 were obtained using
HPLC Methods 1 or 2. One retention time is shown for
most of these examples. The two isomers that comprise
these radiopharmaceuticals are usually not completely
resolved by these HPLC methods. Typically there is a
10 shoulder on the main peak reported.

Analytical Methods

HPLC Method 1

Column: Vydac C₁₈ (4.6 mm x 25 cm)

15 Flow rate: 1 mL/min

Solvent A = 0.01 M pH 6 phosphate buffer

Solvent B = acetonitrile

Gradient:

t = 0 min 100% A

t = 15 min 70% A, 30% B

t = 25 min 25% A, 75% B

Detection by sodium iodide probe

HPLC Method 2

5 Column: Zorbax Rx C₁₈ (4.6 mm x 25 cm)

Flow rate: 1 mL/min

Solvent A = 90:10 0.025 M pH 8 phosphate buffer
:acetonitrile

Solvent B = 50:50 0.025 M pH 8 phosphate buffer

10 :acetonitrile

Gradient:

t = 0 min 100% A

t = 25 min 100% B

Detection by sodium iodide probe

15

Utility

20 The radiopharmaceuticals provided herein are useful
as imaging agents for the diagnosis of cardiovascular
disorders, such as thromboembolic disease or
atherosclerosis, infectious disease and cancer. The
radiopharmaceuticals are comprised of technetium-99m
25 labeled hydrazino or diazenido modified biologically
active molecules that selectively localize at sites of
disease and thus allow an image to be obtained of the
loci using gamma scintigraphy.

Canine Deep Vein Thrombosis Model: This model
30 incorporates the triad of events (hypercoagulatable
state, period of stasis, low shear environment)
essential for the formation of a venous fibrin-rich
actively growing thrombus. The procedure was as

follows: Adult mongrel dogs of either sex (9-13 kg) were anesthetized with pentobarbital sodium (35 mg/kg, i.v.) and ventilated with room air via an endotracheal tube (12 strokes/min, 25 ml/kg). For
5 arterial pressure determination, the right femoral artery was cannulated with a saline-filled polyethylene catheter (PE-240) and connected to a Statham pressure transducer (P23ID; Oxnard, CA). Mean arterial blood pressure was determined via damping the pulsatile
10 pressure signal. Heart rate was monitored using a cardiometer (Biotach, Grass Quincy, MA) triggered from a lead II electrocardiogram generated by limb leads. The right femoral vein was cannulated (PE-240) for drug administration. A 5 cm segment of both jugular
15 veins was isolated, freed from fascia and circumscribed with silk suture. A microthermister probe was placed on the vessel which serves as an indirect measure of venous flow. A balloon embolectomy catheter was utilized to induce the 15 min period of stasis during which time a
20 hypercoagulatable state was then induced using 5 U thrombin (American Diagnostica, Greenwich CT) administered into the occluded segment. Fifteen minutes later, flow was reestablished by deflating the balloon. The radiopharmaceutical was infused during the first 5
25 minutes of reflow and the rate of incorporation monitored using gamma scintigraphy.

Canine Arteriovenous Shunt Model: Adult mongrel dogs of either sex (9-13kg) were anesthetized with
30 pentobarbital sodium (35 mg/kg, i.v.) and ventilated with room air via an endotracheal tube (12 strokes/min, 25 ml/kg). For arterial pressure determination, the left carotid artery was cannulated with a saline-filled polyethylene catheter (PE-240) and connected to a
35 Statham pressure transducer (P23ID; Oxnard, CA). Mean arterial blood pressure was determined via damping the pulsatile pressure signal. Heart rate was monitored

using a cardiometer (Biotach, Grass Quincy, MA) triggered from a lead II electrocardiogram generated by limb leads. A jugular vein was cannulated (PE-240) for drug administration. The both femoral arteries and
5 femoral veins were cannulated with silicon treated (Sigmacote, Sigma Chemical Co. St Louis, MO), saline filled polyethylene tubing (PE-200) and connected with a 5 cm section of silicon treated tubing (PE-240) to form an extracorporeal arterio-venous shunts (A-V). Shunt
10 patency was monitored using a doppler flow system (model VF-1, Crystal Biotech Inc, Hopkinton, MA) and flow probe (2-2.3 mm, Titronics Med. Inst., Iowa City, IA) placed proximal to the locus of the shunt. All parameters were monitored continuously on a polygraph recorder (model 7D
15 Grass) at a paper speed of 10 mm/min or 25 mm/sec.

On completion of a 15 min post surgical stabilization period, an occlusive thrombus was formed by the introduction of a thrombogenic surface (4-0
20 braided silk thread, 5 cm in length, Ethicon Inc., Somerville, NJ) into the shunt one shunt with the other serving as a control. Two consecutive 1hr shunt periods were employed with the test agent administered as an infusion over 5 min beginning 5 min before insertion of
25 the thrombogenic surface. At the end of each 1 hr shunt period the silk was carefully removed and weighed and the % incorporation determined via well counting. Thrombus weight was calculated by subtracting the weight of the silk prior to placement from the total weight of
30 the silk on removal from the shunt. Arterial blood was withdrawn prior to the first shunt and every 30 min thereafter for determination of blood clearance, whole blood collagen-induced platelet aggregation, thrombin-induced platelet degranulation (platelet ATP release),
35 prothrombin time and platelet count. Template bleeding time was also performed at 30 min intervals.

Complexes in which the biologically active molecules, Q, are chemotactic peptides can be evaluated for potential clinical utility as radiopharmaceuticals for the diagnosis of infection by performing imaging studies in a guinea pig model of focal infection.

Guinea Pig Focal Infection Model: Hartley guinea pigs; unspecified sex; weight between 200-250 grams are fasted overnight prior to the procedure. Each guinea pig is anesthetized with a mixture of ketamine 25-55 mg/kg//IM and xylazine 2-5 mg/kg/IM. A #10 trochar needle is used to introduce a 2 inch piece of umbilical string that has been immersed in a 6% sodium caseinate solution (this is the chemoattractant) into the right flank and is placed on the left side of the peritoneal cavity. The placement of the chemoattractant serves as a focal site for white blood cell recruitment. The puncture site is sealed with Nexabain, a skin glue (if required). The animals are allowed to recover for 18 hrs.

Eighteen hours later the guinea pigs are anesthetized with kettamine 25-55 mg/kg//IM and xylazine 2-5 mg/kg/IM to achieve Stage III/Plane III of anesthesia and insure proper injection of the test agent into the lateral saphenous vein. Once the test agent is administered the guinea pigs are placed behind a lead shield and monitored for 1-4 hours. At the appropriate time postinjection, the animals are euthanized with pentobarbital sodium 65 mg/kg, I.V.. and a biodistribution performed. Throughout the course of the study, blood samples are withdrawn via cardiac puncture.


Results

The results of the evaluation of the radiopharmaceutical of Example 1 in the Canine

Arteriovenous Shunt model is shown in Figure 1. Included are results for the positive control, In-111-labeled autologous platelets and the negative controls, Tc-99m-albumin and I-125-fibrinogen. All values are for the first 1 hour shunt period. The data show that the radiopharmaceutical of Example 1 is taken up in thrombi under both mixed arterial and venous conditions equivalently to the positive control and to a significantly greater extent than the negative controls. The thrombus-to-blood ratios (target-to-background ratios), 114 (mixed arterial) and 3.1 (venous) indicate that the thrombi can be readily differentiated from the surrounding tissue and fluid by standard imaging techniques familiar to those skilled in the art. The important advantage of the radiopharmaceutical of Example 1 over the positive control, In-111-platelets, is that the laborious extracorporeal labeling procedure used to label autologous platelets with In-111 is not necessary. This shortens the time needed to obtain diagnostic information and avoids the potential risk of exposure of the nuclear medicine practitioner to blood-borne pathogens, such as HIV.

WE CLAIM:

1. A radiopharmaceutical comprising a first ancillary ligand, a second ancillary ligand capable of stabilizing the radiopharmaceutical, a transition metal radionuclide, a transition metal chelator, a biologically active group connected to said chelator, optionally having a linking group between said chelator and said biologically active group.
2. The radiopharmaceutical of Claim 1 having a linking group between said chelator and said biologically active group.
3. The radiopharmaceutical of Claim 2 of formula:




and pharmaceutically acceptable salts thereof wherein,


Q is a biologically active group;

d' is 1 to 20;

L_n is a linking group of formula:



wherein:



M^2 is $-(CR^{55}R^{56})_g-[Z^1(CH_2)_g]_{g'}-$;

g is independently 0-10;

5

g' is independently 0-1;

g'' is independently 0-10;

f is independently 0-10;

10

f' is independently 0-10;

f'' is independently 0-1;

15

Y^1 and Y^2 , at each occurrence, are independently selected from:

a bond, O, NR^{56} , $C=O$, $C(=O)O$, $OC(=O)O$, $C(=O)NH-$, $C=NR^{56}$, S, SO, SO_2 , SO_3 , $NHC(=O)$, $(NH)_2C(=O)$, $(NH)_2C=S$;

20

Z^1 is independently selected at each occurrence from a C_6-C_{14} saturated, partially saturated, or aromatic carbocyclic ring system, substituted with 0-4 R^{57} ; and a heterocyclic ring system, optionally substituted with 0-4 R^{57} ;

25

30

R^{55} and R^{56} are independently selected at each occurrence from:

hydrogen, C_1-C_{10} alkyl substituted with 0-5 R^{57} , alkaryl wherein the aryl is substituted with 0-5 R^{57} ;

35

5 R⁵⁷ is independently selected at each occurrence from the group: hydrogen, OH, NHR⁵⁸, C(=O)R⁵⁸, OC(=O)R⁵⁸, OC(=O)OR⁵⁸, C(=O)OR⁵⁸, C(=O)NR⁵⁸, C≡N, SR⁵⁸, SOR⁵⁸, SO₂R⁵⁸, NHC(=O)R⁵⁸, NHC(=O)NHR⁵⁸, NHC(=S)NHR⁵⁸, or, alternatively, when attached to an additional molecule Q, R⁵⁷ is independently selected at each occurrence from the group: O, NR⁵⁸, C=O, C(=O)O, OC(=O)O, C(=O)N, C=NR⁵⁸, S, SO, SO₂, SO₃, NHC(=O), (NH)₂C(=O), (NH)₂C=S; and

15 R⁵⁸ is independently selected at each occurrence from the group: hydrogen, C₁-C₆ alkyl, benzyl, and phenyl;

20 x, y and z are independently 1 or 2;

25 M_t is a transition metal radionuclide selected from the group: ^{99m}Tc, ¹⁸⁶Re and ¹⁸⁸Re;

30 Ch is a radionuclide metal chelator coordinated to transition metal radionuclide M_t, and is independently selected at each occurrence, from the group: R⁴⁰N=N+=, R⁴⁰R⁴¹N-N=, and R⁴⁰N=N(H)-; wherein

35 R⁴⁰ is independently selected at each occurrence from the group: a bond to L_n, C₁-C₁₀ alkyl substituted with 0-3 R⁵², aryl substituted with 0-3 R⁵², cycloalkyl substituted with 0-3 R⁵², heterocycle

substituted with 0-3 R^{52} ,
 heterocycloalkyl substituted with 0-3
 R^{52} , aralkyl substituted with 0-3 R^{52} and
 alkaryl substituted with 0-3 R^{52} ;

5

R^{41} is independently selected from the group:
 hydrogen, aryl substituted with 0-3 R^{52} ,
 C_1 - C_{10} alkyl substituted with 0-3 R^{52} ,
 and a heterocycle substituted with 0-3
 R^{52} ;

10

R^{52} is independently selected at each
 occurrence from the group: a bond to L_n ,
 $=O$, F , Cl , Br , I , $-CF_3$, $-CN$, $-CO_2R^{53}$,
 $-C(=O)R^{53}$, $-C(=O)N(R^{53})_2$, $-CHO$, $-CH_2OR^{53}$,
 $-OC(=O)R^{53}$, $-OC(=O)OR^{53a}$, $-OR^{53}$,
 $-OC(=O)N(R^{53})_2$, $-NR^{53}C(=O)R^{53}$, $-N(R^{53})_3^+$,
 $-NR^{54}C(=O)OR^{53a}$, $-NR^{53}C(=O)N(R^{53})_2$,
 $-NR^{54}SO_2N(R^{53})_2$, $-NR^{54}SO_2R^{53a}$, $-SO_3H$,
 $-SO_2R^{53a}$, $-SR^{53}$, $-S(=O)R^{53a}$, $-SO_2N(R^{53})_2$,
 $-N(R^{53})_2$, $-NHC(=NH)NHR^{53}$, $-C(=NH)NHR^{53}$,
 $=NOR^{53}$, NO_2 , $-C(=O)NHR^{53}$,
 $-C(=O)NHN(R^{53})R^{53a}$, $-OCH_2CO_2H$,
 2-(1-morpholino)ethoxy;

15

20

25

R^{53} , R^{53a} , and R^{54} are each independently
 selected at each occurrence from the
 group: hydrogen, C_1 - C_6 alkyl, and a bond
 to L_n ;

30


A_{L1} is a first ancillary ligand selected from the
 group:

dioxygen ligand and
 functionalized aminocarboxylate;

35

A_{L2} is an ancillary ligand capable of stabilizing the radiopharmaceutical selected from the group:

5



wherein

10

n is 0 or 1;

X^1 is independently selected at each occurrence from the group: CR^{64} and N ;

15

X^2 is independently selected at each occurrence from the group: CR^{64} , $CR^{64}R^{64}$, N , NR^{64} , O and S ;

20

X^3 is independently selected at each occurrence from the group: C , CR^{64} , and N ;

25

provided the total number of heteroatoms in each ring of the ligand A_{L2} is 1 to 4;

Y is selected from the group: BR^{64-} , CR^{64} , $(P=O)$, $(P=S)$;

30

and a , b , c , d , e and f indicate the positions of optional double

bonds, provided that one of e and f is a double bond;

5

R^{64} is independently selected at each occurrence from the group:

10

H, C_1 - C_{10} alkyl substituted with 0-3 R^{65} , C_2 - C_{10} alkenyl substituted with 0-3 R^{65} , C_2 - C_{10} alkynyl substituted with 0-3 R^{65} , aryl substituted with 0-3 R^{65} , carbocycle substituted with 0-3 R^{65} , and R^{65} ;

15

20

or, alternatively, two R^{64} may be taken together with the atom or atoms to which they are attached to form a fused aromatic, carbocyclic or heterocyclic ring, substituted with 0-3 R^{65} ;

25

30

R^{65} is independently selected at each occurrence from the group: =O, F, Cl, Br, I, $-CF_3$, $-CN$, $-NO_2$, $-CO_2R^{66}$, $-C(=O)R^{66}$, $-C(=O)N(R^{66})_2$, $-N(R^{66})_3^+$, $-CH_2OR^{66}$, $-OC(=O)R^{66}$, $-OC(=O)OR^{66a}$, $-OR^{66}$, $-OC(=O)N(R^{66})_2$, $-NR^{66}C(=O)R^{66}$, $-NR^{67}C(=O)OR^{66a}$, $-NR^{66}C(=O)N(R^{66})_2$,

35

-NR⁶⁷SO₂N(R⁶⁶)₂,
 -NR⁶⁷SO₂R^{66a}, -SO₃H,
 -SO₂R^{66a}, -SO₂N(R⁶⁶)₂,
 -N(R⁶⁶)₂, -OCH₂CO₂H; and

5

R⁶⁶, R^{66a}, and R⁶⁷ are each
 independently selected at
 each occurrence from the
 group: hydrogen and C₁-C₆
 alkyl.

10

4. The radiopharmaceutical of Claim 3 wherein:

15 Q is a biologically active molecule selected from
 the group: IIb/IIIa receptor antagonists,
 IIb/IIIa receptor ligands, fibrin binding
 peptides, leukocyte binding peptides,
 chemotactic peptides, somatostatin analogs,
 20 and selectin binding peptides;

d' is 1 to 3;

25

L_n is:

- (CR⁵⁵R⁵⁶)_g - [Y¹ (CR⁵⁵R⁵⁶)_f Y²]_f - (CR⁵⁵R⁵⁶)_g - ,

wherein:

30

g" is 0-5;

f is 0-5;

35

f' is 1-5;

Y¹ and Y², at each occurrence, are
 independently selected from:

O, NR^{56} , $\text{C}=\text{O}$, $\text{C}(=\text{O})\text{O}$, $\text{OC}(=\text{O})\text{O}$,
 $\text{C}(=\text{O})\text{NH}$, $\text{C}=\text{NR}^{56}$, S , SO , SO_2 , SO_3 ,
 $\text{NHC}(=\text{O})$, $(\text{NH})_2\text{C}(=\text{O})$, $(\text{NH})_2\text{C}=\text{S}$;

5

R^{55} and R^{56} are independently selected at
each occurrence from:

10

hydrogen, C_1 - C_{10} alkyl and alkaryl;

x and y are 1;

M_t is ^{99m}Tc ;

15

Ch is selected from the group: $\text{R}^{40}\text{N}=\text{N}^+=$ and
 $\text{R}^{40}\text{R}^{41}\text{N}=\text{N}$; wherein

20

R^{40} is independently selected at each
occurrence from the group: aryl
substituted with 0-3 R^{52} , and heterocycle
substituted with 0-3 R^{52} ;

25

R^{41} is independently selected from the group:
hydrogen, aryl substituted with 0-1 R^{52} ,
 C_1 - C_3 alkyl substituted with 0-1 R^{52} , and
a heterocycle substituted with 0-1 R^{52} ;

30

R^{52} is independently selected at each
occurrence from the group: a bond to L_n ,
 $-\text{CO}_2\text{R}^{53}$, $-\text{CH}_2\text{OR}^{53}$, $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{R}^{53a}$,
 $-\text{N}(\text{R}^{53})_2$, $-\text{N}(\text{R}^{53})_3^+$, $-\text{NHC}(=\text{NH})\text{NHR}^{53}$, and
 $-\text{OCH}_2\text{CO}_2\text{H}$;

35

R⁵³ and R^{53a} are each independently selected at each occurrence from the group: hydrogen and C₁-C₃ alkyl;

5 AL₁ is a functionalized aminocarboxylate;

n is 0;

Y is BR⁶⁴-;

10

R⁶⁴ is independently selected at each occurrence from the group:

15

H, C₁-C₃ alkyl substituted with 0-3 R⁶⁵, aryl substituted with 0-3 R⁶⁵, and R⁶⁵;

20

or, alternatively, two R⁶⁴ may be taken together with the atom or atoms to which they are attached to form a fused aromatic or heterocyclic ring, substituted with 0-3 R⁶⁵;

25

30

R⁶⁵ is independently selected at each occurrence from the group: -NO₂, -CO₂R⁶⁶, -OR⁶⁶, -SO₃H, and -OCH₂CO₂H; and

35

R⁶⁶ is hydrogen.

5. The radiopharmaceutical of Claim 4 wherein:

Q is a biologically active molecule selected from the group: IIb/IIIa receptor antagonists and chemotactic peptides;

5

d' is 1;

y¹ and y², at each occurrence, are independently selected from:

10

O, NR⁵⁶, C=O, C(=O)O, OC(=O)O, C(=O)NH, C=NR⁵⁶, NHC(=O), (NH)₂C(=O);

15

R⁵⁵ and R⁵⁶ are hydrogen;

z is 1;

20

R⁴⁰ is heterocycle substituted with R⁵²;

R⁴¹ is hydrogen;

25

R⁵² is a bond to L_n;

A_{L1} is tricine;

X² is independently selected at each occurrence from the group: CR⁶⁴,

30

CR⁶⁴R⁶⁴, N, NR⁶⁴ and O;

X³ is N;

provided the total number of heteroatoms in each ring of the ligand A_{L2} is 2 to 3;

35


R⁶⁴ is independently selected at each occurrence from the group:

5 H, C₁-C₃ alkyl substituted with 0-1 R⁶⁵, aryl substituted with 0-1 R⁶⁵, and R⁶⁵;

10 R⁶⁵ is independently selected at each occurrence from the group: -NO₂, -CO₂R⁶⁶, -OR⁶⁶, and -SO₃H.

15 6. The radiopharmaceutical of Claim 3 wherein:

Q is





20

d' is 1;


L_n is attached to Q at the carbon atom designated with a * and has the formula:

25





or



Ch⁺ is

is attached to L_N at the carbon atom designated with a *;





5 M_t is ^{99m}Tc;

A_{L1} is tricine;




x, y and z are 1;

10




and A_{L2} is selected from the group:




15



20





- 5 7. A method for radioimaging a mammal comprising (i) administering to said mammal an effective amount of a radiopharmaceutical of any of Claims 1-6, and (ii) scanning the mammal using a radioimaging device.
- 10 8. A method for visualizing sites of platelet deposition in a mammal by radioimaging, comprising (i) administering to said mammal an effective amount of a radiopharmaceutical of any of Claims 1-6, and (ii) scanning the mammal using a radioimaging device.
- 15 9. A method of determining platelet deposition in a mammal comprising administering to said mammal a radiopharmaceutical composition of any of Claims 1-6, and imaging said mammal.
- 20 10. A method of diagnosing a disorder associated with platelet deposition in a mammal comprising administering to said mammal a radiopharmaceutical composition of any of Claims 1-6, and imaging said mammal.
- 25 11. A kit for preparing a radiopharmaceutical comprising:
- 30

- (a) a predetermined quantity of a sterile, pharmaceutically acceptable reagent of formula:




- (b) a predetermined quantity of a sterile, pharmaceutically acceptable first ancillary ligand, AL_1 , selected from the group:

10

dioxygen ligand and
functionalized aminocarboxylate;

15

- (c) a predetermined quantity of a sterile, pharmaceutically acceptable second ancillary ligand, AL_2 , selected from the group:



20

- (d) a predetermined quantity of a sterile, pharmaceutically acceptable reducing agent;
and

25

- (e) optionally, a predetermined quantity of one or more sterile, pharmaceutically acceptable components selected from the group: transfer ligands, buffers, lyophilization aids, stabilization aids, solubilization aids and

30

wherein:

Q is a biologically active molecule;

5 d' is 1 to 20;

L_n is a linking group of formula:

10 $M^1 - [Y^1 (CR^{55}R^{56})_f (Z^1)_{f'} Y^2]_{f''} - M^2$,

wherein:

15 M^1 is $-[(CH_2)_g Z^1]_{g'} - (CR^{55}R^{56})_{g''}$;

M^2 is $-(CR^{55}R^{56})_{g''} - [Z^1 (CH_2)_g]_{g'}$;

g is independently 0-10;

20 g' is independently 0-1;

g'' is independently 0-10;

25 f is independently 0-10;

f' is independently 0-10;

f'' is independently 0-1;

30 Y^1 and Y^2 , at each occurrence, are independently selected from:

35 a bond, O, NR^{56} , C=O, C(=O)O, OC(=O)O, C(=O)NH-, C=NR⁵⁶, S, SO, SO₂, SO₃, NHC(=O), (NH)₂C(=O), (NH)₂C=S;

5 Z¹ is independently selected at each occurrence from a C₆-C₁₄ saturated, partially saturated, or aromatic carbocyclic ring system, substituted with 0-4 R⁵⁷, and a heterocyclic ring system, optionally substituted with 0-4 R⁵⁷;

10 R⁵⁵ and R⁵⁶ are independently selected at each occurrence from:

15 hydrogen; C₁-C₁₀ alkyl substituted with 0-5 R⁵⁷, alkaryl wherein the aryl is substituted with 0-5 R⁵⁷;

20 R⁵⁷ is independently selected at each occurrence from the group: hydrogen, OH, NHR⁵⁸, C(=O)R⁵⁸, OC(=O)R⁵⁸, OC(=O)OR⁵⁸, C(=O)OR⁵⁸, C(=O)NR⁵⁸, C≡N, SR⁵⁸, SOR⁵⁸, SO₂R⁵⁸, NHC(=O)R⁵⁸, NHC(=O)NHR⁵⁸, NHC(=S)NHR⁵⁸; or, alternatively, when attached to an additional molecule Q, R⁵⁷ is independently selected at each occurrence from the group: O, NR⁵⁸, C=O, C(=O)O, OC(=O)O, C(=O)N, C=NR⁵⁸, S, SO, SO₂, SO₃, NHC(=O), (NH)₂C(=O), (NH)₂C=S; and,

30 R⁵⁸ is independently selected at each occurrence from the group: hydrogen, C₁-C₆ alkyl, benzyl, and phenyl;

35

C_h is a radionuclide metal chelator selected from the group: $R^{40}R^{41}N-N=C(C_1-C_3 \text{ alkyl})_2$ and $R^{40}NNH_2-$, and $R^{40}R^{41}N-N=CR^{80}R^{81}$, wherein,

5 R^{40} is independently selected at each occurrence from the group: a bond to L_n , C_1-C_{10} alkyl substituted with 0-3 R^{52} , aryl substituted with 0-3 R^{52} , cycloalkyl substituted with 0-3 R^{52} , heterocycle substituted with 0-3 R^{52} , heterocycloalkyl substituted with 0-3 R^{52} , aralkyl substituted with 0-3 R^{52} and alkaryl substituted with 0-3 R^{52} ;


15 R^{41} is independently selected from the group: hydrogen, aryl substituted with 0-3 R^{52} , C_1-C_{10} alkyl substituted with 0-3 R^{52} , and a heterocycle substituted with 0-3 R^{52} ;

25 R^{52} is independently selected at each occurrence from the group: a bond to L_n , $=O$, F , Cl , Br , I , $-CF_3$, $-CN$, $-CO_2R^{53}$, $-C(=O)R^{53}$, $-C(=O)N(R^{53})_2$, $-CHO$, $-CH_2OR^{53}$, $-OC(=O)R^{53}$, $-OC(=O)OR^{53a}$, $-OR^{53}$, $-OC(=O)N(R^{53})_2$, $-NR^{53}C(=O)R^{53}$, $-NR^{54}C(=O)OR^{53a}$, $-N(R^{53})_3^+$, $-NR^{53}C(=O)N(R^{53})_2$, $-NR^{54}SO_2N(R^{53})_2$, $-NR^{54}SO_2R^{53a}$, $-SO_3H$, $-SO_2R^{53a}$, $-SR^{53}$, $-S(=O)R^{53a}$, $-SO_2N(R^{53})_2$, $-N(R^{53})_2$, $-NHC(=NH)NHR^{53}$, $-C(=NH)NHR^{53}$, $=NOR^{53}$, NO_2 , $-C(=O)NHOR^{53}$, $-C(=O)NHN(R^{53})R^{53a}$, $-OCH_2CO_2H$, 2-(1-morpholino)ethoxy;

R^{53} , R^{53a} , and R^{54} are each independently selected at each occurrence from the group: hydrogen, C₁-C₆ alkyl, and a bond to L_n ;

R^{80} and R^{81} are independently selected from the group:
 H, C₁-C₁₀ alkyl, -CN, -CO₂ R^{85} ,
 -C(=O) R^{85} , -C(=O)N(R^{85})₂, C₂ - C₁₀ 1-alkene substituted with 0-3 R^{84} , C₂ - C₁₀ 1-alkyne substituted with 0-3 R^{84} , aryl substituted with 0-3 R^{84} , unsaturated heterocycle substituted with 0-3 R^{84} , and unsaturated carbocycle substituted with 0-3 R^{84} , provided that when one of R^{80} and R^{81} is H or alkyl, then the other is not H or alkyl;

or, alternatively, R^{80} and R^{81} , may be taken together with the shown divalent carbon radical to form:



wherein:

R^{82} and R^{83} may be independently selected from the group:
 H, R^{84} , C₁-C₁₀ alkyl substituted with 0-3 R^{84} , C₂-C₁₀ alkenyl substituted with

5 0-3 R⁸⁴, C₂-C₁₀ alkynyl
substituted with 0-3 R⁸⁴, aryl
substituted with 0-3 R⁸⁴,
heterocycle substituted with
0-3 R⁸⁴ and carbocycle
substituted with 0-3 R⁸⁴;

10 or, alternatively, R⁸², R⁸³ may be
taken together to form a fused
aromatic or heterocyclic ring;

15 R⁸⁴ is independently selected
at each occurrence from
the group: =O, F, Cl,
Br, I, -CF₃, -CN, -CO₂R⁸⁵,
-C(=O)R⁸⁵, -C(=O)N(R⁸⁵)₂,
-N(R⁸⁵)₃⁺ -CH₂OR⁸⁵,
20 -OC(=O)R⁸⁵, -OC(=O)OR^{85a},
-OR⁸⁵, -OC(=O)N(R⁸⁵)₂,
-NR⁸⁵C(=O)R⁸⁵,
-NR⁸⁶C(=O)OR^{85a},
-NR⁸⁵C(=O)N(R⁸⁵)₂,
-NR⁸⁶SO₂N(R⁸⁵)₂,
25 -NR⁸⁶SO₂R^{85a}, -SO₃H,
-SO₂R^{85a}, -SR⁸⁵,
-S(=O)R^{85a}, -SO₂N(R⁸⁵)₂,
-N(R⁸⁵)₂, -NHC(=NH)NHR⁸⁵,
-C(=NH)NHR⁸⁵, =NOR⁸⁵,
30 -C(=O)NHOR⁸⁵, -OCH₂CO₂H,
2- (1-morpholino)ethoxy;
and

35 R⁸⁵, R^{85a}, and R⁸⁶ are each
independently selected at
each occurrence from the

group: hydrogen and C₁-C₆
alkyl.

5 X¹ is independently selected at each
occurrence from the group: CR⁶⁴ and
N;

10 X² is independently selected at each
occurrence from the group: CR⁶⁴,
CR⁶⁴R⁶⁴, N, NR⁶⁴, O and S;

15 X³ is independently selected at each
occurrence from the group: C, CR⁶⁴,
and N;

Y is selected from the group: BR⁶⁴-,
CR⁶⁴, (P=O), (P=S);

20 provided the total number of heteroatoms
in each ring of the heterocycle is
1 to 4;

25 R⁶⁴ is independently selected at each
occurrence from the group:

30 H, C₁-C₁₀ alkyl substituted
with 0-3 R⁶⁵, C₂ - C₁₀ alkenyl
substituted with 0-3 R⁶⁵, C₂ -
C₁₀ alkynyl substituted with 0-
3 R⁶⁵, aryl substituted with 0-
3 R⁶⁵, carbocycle substituted
with 0-3 R⁶⁵ and R⁶⁵;

35 or, alternatively, two R⁶⁴ may be
taken together with the atom

or atoms to which they are
attached to form a fused
aromatic, carbocyclic or
heterocyclic ring, substituted
with 0-3 R⁶⁵;

R⁶⁵ is independently selected
at each occurrence from
the group: =O, F, Cl,
Br, I, -CF₃, -CN, -NO₂,
-CO₂R⁶⁶, -C(=O)R⁶⁶,
-C(=O)N(R⁶⁶)₂, -N(R⁶⁶)₃⁺
-CH₂OR⁶⁶, -OC(=O)R⁶⁶,
-OC(=O)OR^{66a}, -OR⁶⁶,
-OC(=O)N(R⁶⁶)₂,
-NR⁶⁶C(=O)R⁶⁶,
-NR⁶⁷C(=O)OR^{66a},
-NR⁶⁶C(=O)N(R⁶⁶)₂,
-NR⁶⁷SO₂N(R⁶⁶)₂,
-NR⁶⁷SO₂R^{66a}, -SO₃H,
-SO₂R^{66a}, -SO₂N(R⁶⁶)₂,
-N(R⁶⁶)₂, -OCH₂CO₂H; and

R⁶⁶, R^{66a}, and R⁶⁷ are each
independently selected at
each occurrence from the
group: hydrogen and C₁-C₆
alkyl.

n is 0 or 1;

and a, b, c, d, e and f indicate the
positions of optional double bonds,
provided that one of e and f.

12. The kit of Claim 11, wherein:

AL1 is a functionalized aminocarboxylate;

Q is a biologically active molecule selected from
the group: IIb/IIIa receptor antagonists,
IIb/IIIa receptor ligands, fibrin binding
peptides, leukocyte binding peptides,
chemotactic peptides, somatostatin analogs,
and selectin binding peptides;

d' is 1 to 3;

L_n is:

$-(CR^{55}R^{56})_{g''}-[Y^1(CR^{55}R^{56})_fY^2]_{f'}-(CR^{55}R^{56})_{g''}-$,

wherein:

g'' is 0-5;

f is 0-5;

f' is 1-5;

Y¹ and Y², at each occurrence, are
independently selected from:

O, NR⁵⁶, C=O, C(=O)O, OC(=O)O,
C(=O)NH, C=NR⁵⁶, S, SO, SO₂, SO₃,
NHC(=O), (NH)₂C(=O), (NH)₂C=S;


R⁵⁵ and R⁵⁶ are independently selected at
each occurrence from:

hydrogen; C₁-C₁₀ alkyl and alkaryl;

- 5 R^{40} is independently selected at each occurrence from the group: aryl substituted with 0-3 R^{52} , and heterocycle substituted with 0-3 R^{52} ;
- 10 R^{41} is independently selected from the group: hydrogen, aryl substituted with 0-1 R^{52} , C_1-C_3 alkyl substituted with 0-1 R^{52} , and a heterocycle substituted with 0-1 R^{52} ;
- 15 R^{52} is independently selected at each occurrence from the group: a bond to L_n , $-CO_2R^{53}$, $-CH_2OR^{53}$, $-SO_3H$, $-SO_2R^{53a}$, $-N(R^{53})_2$, $-N(R^{53})_3^+$, $-NHC(=NH)NHR^{53}$, and $-OCH_2CO_2H$;
- 20 R^{53} and R^{53a} are each independently selected at each occurrence from the group: hydrogen and C_1-C_3 alkyl;
- 25 R^{80} is independently selected at each occurrence from the group:
 $-CO_2R^{85}$, $C_2 - C_5$ 1-alkene
30 substituted with 0-3 R^{84} , $C_2 - C_5$ 1-alkyne substituted with 0-3 R^{84} ,
 aryl substituted with 0-3 R^{84} , and
 unsaturated heterocycle substituted
 with 0-3 R^{84} ;
- 35 R^{81} is independently selected at each occurrence from the group: H and C_1-C_5 alkyl;

or, alternatively, R^{80} and R^{81} , may be taken together with the shown divalent carbon radical to form:

5



wherein:

10

R^{82} and R^{83} may be independently selected from the group:
H and R^{84} ;

15

or, alternatively, R^{82} , R^{83} may be taken together to form a fused aromatic or heterocyclic ring;

20

R^{84} is independently selected at each occurrence from the group: $-\text{CO}_2R^{85}$, $-\text{C}(=\text{O})\text{N}(R^{85})_2$, $-\text{CH}_2\text{OR}^{85}$, $-\text{OC}(=\text{O})R^{85}$, $-\text{OR}^{85}$, $-\text{SO}_3\text{H}$, $-\text{N}(R^{85})_2$, and $-\text{OCH}_2\text{CO}_2\text{H}$;

25

30

R^{85} is independently selected at each occurrence from the group: hydrogen and $\text{C}_1\text{-C}_3$ alkyl.

Y is BR^{64-} ;

R⁶⁴ is independently selected at each occurrence from the group:

5 H, C₁-C₃ alkyl substituted with
0-3 R⁶⁵, aryl substituted with
0-3 R⁶⁵ and R⁶⁵;

10 or, alternatively, two R⁶⁴ may be
taken together with the atom
or atoms to which they are
attached to form a fused
aromatic, or heterocyclic
ring, substituted with 0-3 R⁶⁵;

15 R⁶⁵ is independently selected
at each occurrence from
the group: -NO₂,
20 -CO₂R⁶⁶, -OR⁶⁶, -SO₃H,
and -OCH₂CO₂H;

R⁶⁶ is hydrogen; and

25 n is 0.

13. The kit of Claim 11, wherein:

30 AL1 is a tricine;

Q is a biologically active molecule selected from
the group: IIb/IIIa receptor antagonists, and
chemotactic peptides;

35 d' is 1;

y¹ and y², at each occurrence, are independently selected from:

5 O, NR⁵⁶, C=O, C(=O)O, OC(=O)O,
C(=O)NH, C=NR⁵⁶, NHC(=O),
(NH)₂C(=O);

10 R⁵⁵ and R⁵⁶ are hydrogen;

R⁴⁰ is heterocycle substituted with R⁵²;

R⁴¹ is hydrogen;

15 R⁵² is a bond to L_n;

R⁸⁰ is independently selected at each occurrence from the group:
-CO₂R⁸⁵, C₂ - C₃ 1-alkene
20 substituted with 0-1 R⁸⁴, aryl
substituted with 0-1 R⁸⁴, and
unsaturated heterocycle substituted
with 0-1 R⁸⁴;

25 R⁸¹ is H;

R⁸⁴ is independently selected at each occurrence from the group:
-CO₂R⁸⁵, -OR⁸⁵,
30 -SO₃H, and -N(R⁸⁵)₂;

R⁸⁵ is independently selected at each occurrence from the group: hydrogen and methyl;

35


- X¹ is independently selected at each occurrence from the group: CR⁶⁴ and N;
- 5 X² is independently selected at each occurrence from the group: CR⁶⁴, CR⁶⁴R⁶⁴, N, NR⁶⁴, and O;
- 10 X³ is N;
- Y is BR⁶⁴-;
- 15 provided the total number of heteroatoms in each ring of the ligand A_{L2} is 2 to 3;
- R⁶⁴ is independently selected at each occurrence from the group:
- 20 H, C₁-C₃ alkyl substituted with 0-1 R⁶⁵, aryl substituted with 0-1 R⁶⁵, and R⁶⁵;
- 25 R⁶⁵ is independently selected at each occurrence from the group: -NO₂, -CO₂R⁶⁶, -OR⁶⁶, and -SO₃H;
- 30 R⁶⁶ is hydrogen;
- n is 0;
- 35 and a, b, c, d, e and f indicate the positions of optional double bonds, provided that one of e and f is a double bond.

14. The kit of Claim 11, wherein:


5

AL2 is selected from the group:


10




15



20



Q is




5

d' is 1;

10

L_n is attached to Q at the carbon atom designated with a * and has the formula:



15

C_h is selected from $R^{40}NNH_2-$ and $R^{40}R^{41}N-N=CR^{80}R^{81}$, wherein,

20

R^{40} is independently selected at each occurrence from the group: heterocycle substituted with R^{52} ;

25

R^{41} is hydrogen;

R^{52} is a bond to L_n ;

5 R^{80} is independently selected at each
 occurrence from the group:
 $-CO_2R^{85}$, $C_2 - C_3$ 1-alkene
 substituted with 0-1 R^{84} , aryl
 substituted with 0-1 R^{84} and
 unsaturated heterocycle substituted
 with 0-1 R^{84} ;

10 R^{81} is H;

15 R^{84} is independently selected at
 each occurrence from the
 group: $-CO_2R^{85}$, $-OR^{85}$,
 $-SO_3H$, and $-N(R^{85})_2$;

20 R^{85} is independently selected at
 each occurrence from the
 group: hydrogen and methyl.

1/2




FIG. 1a




FIG. 1b

2/2




FIG. 1c




FIG. 1d



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 51/08, C07F 13/00	A3	(11) International Publication Number: WO 97/33627 (43) International Publication Date: 18 September 1997 (18.09.97)																																								
(21) International Application Number: PCT/US97/03915 (22) International Filing Date: 12 March 1997 (12.03.97) (30) Priority Data: 60/013,360 13 March 1996 (13.03.96) US 08/646,866 8 May 1996 (08.05.96) US 08/808,699 28 February 1997 (28.02.97) US (71) Applicant: THE DU PONT MERCK PHARMACEUTICAL COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). (72) Inventors: EDWARDS, David, Scott; 123 Farms Drive, Burlington, MA 01803 (US). LIU, Shuang; 17 Judith Road, Chelmsford, MA 01824 (US). (74) Agent: BOUDREAUX, Gerald, J.; The du Pont Merck Pharmaceutical Company, Legal/Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		(81) Designated States: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 26 February 1998 (26.02.98)																																								
(54) Title: NEW TERNARY RADIOPHARMACEUTICAL COMPLEXES <div style="display: flex; flex-wrap: wrap;"> <div style="width: 50%;"> <p style="text-align: center;">VENOUS CONDITIONS</p> <table border="1"> <caption>VENOUS CONDITIONS - UPTAKE (% ID/g)</caption> <thead> <tr> <th>Compound</th> <th>UPTAKE (% ID/g)</th> </tr> </thead> <tbody> <tr> <td>¹¹¹In-Piotelete</td> <td>0.165</td> </tr> <tr> <td>¹²⁵I-Fibrinogen</td> <td>0.07</td> </tr> <tr> <td>¹²⁵I-Albumin</td> <td>0.05</td> </tr> <tr> <td>Example 1</td> <td>0.101</td> </tr> </tbody> </table> </div> <div style="width: 50%;"> <p style="text-align: center;">VENOUS CONDITIONS</p> <table border="1"> <caption>VENOUS CONDITIONS - IN VIVO SHUNT THROMBUS/BLOOD RATIO</caption> <thead> <tr> <th>Compound</th> <th>Ratio</th> </tr> </thead> <tbody> <tr> <td>¹¹¹In-Piotelete</td> <td>3.24</td> </tr> <tr> <td>¹²⁵I-Fibrinogen</td> <td>1.70</td> </tr> <tr> <td>¹²⁵I-Albumin</td> <td>0.603</td> </tr> <tr> <td>Example 1</td> <td>3.08</td> </tr> </tbody> </table> </div> <div style="width: 50%;"> <p style="text-align: center;">MIXED ARTERIAL CONDITIONS</p> <table border="1"> <caption>MIXED ARTERIAL CONDITIONS - UPTAKE (% ID/g)</caption> <thead> <tr> <th>Compound</th> <th>UPTAKE (% ID/g)</th> </tr> </thead> <tbody> <tr> <td>¹¹¹In-Piotelete</td> <td>5.03</td> </tr> <tr> <td>¹²⁵I-Fibrinogen</td> <td>0.105</td> </tr> <tr> <td>¹²⁵I-Albumin</td> <td>0.037</td> </tr> <tr> <td>Example 1</td> <td>0.7</td> </tr> </tbody> </table> </div> <div style="width: 50%;"> <p style="text-align: center;">MIXED ARTERIAL CONDITIONS</p> <table border="1"> <caption>MIXED ARTERIAL CONDITIONS - IN VIVO SHUNT THROMBUS/BLOOD RATIO</caption> <thead> <tr> <th>Compound</th> <th>Ratio</th> </tr> </thead> <tbody> <tr> <td>¹¹¹In-Piotelete</td> <td>117</td> </tr> <tr> <td>¹²⁵I-Fibrinogen</td> <td>2.09</td> </tr> <tr> <td>¹²⁵I-Albumin</td> <td>0.454</td> </tr> <tr> <td>Example 1</td> <td>114</td> </tr> </tbody> </table> </div> </div> (57) Abstract <p>This invention relates to novel radiopharmaceuticals which are useful as imaging agents for the diagnosis of cardiovascular disorders, infectious disease and cancer, and to kits useful for their preparation. The radiopharmaceuticals of this invention are comprised of a transition metal radionuclide, a transition metal chelator, a biologically active group connected to said chelator, a first ancillary ligand, a second ancillary ligand capable of stabilizing the radiopharmaceutical, optionally having a linking group between said chelator and said biologically active group. Preferred radiopharmaceuticals of this invention have the formula: $[(Q)_d(L_n-CH)_x-M_k(A_{L1})_y(A_{L2})_z]$, wherein the shown variables are as defined herein.</p>			Compound	UPTAKE (% ID/g)	¹¹¹ In-Piotelete	0.165	¹²⁵ I-Fibrinogen	0.07	¹²⁵ I-Albumin	0.05	Example 1	0.101	Compound	Ratio	¹¹¹ In-Piotelete	3.24	¹²⁵ I-Fibrinogen	1.70	¹²⁵ I-Albumin	0.603	Example 1	3.08	Compound	UPTAKE (% ID/g)	¹¹¹ In-Piotelete	5.03	¹²⁵ I-Fibrinogen	0.105	¹²⁵ I-Albumin	0.037	Example 1	0.7	Compound	Ratio	¹¹¹ In-Piotelete	117	¹²⁵ I-Fibrinogen	2.09	¹²⁵ I-Albumin	0.454	Example 1	114
Compound	UPTAKE (% ID/g)																																									
¹¹¹ In-Piotelete	0.165																																									
¹²⁵ I-Fibrinogen	0.07																																									
¹²⁵ I-Albumin	0.05																																									
Example 1	0.101																																									
Compound	Ratio																																									
¹¹¹ In-Piotelete	3.24																																									
¹²⁵ I-Fibrinogen	1.70																																									
¹²⁵ I-Albumin	0.603																																									
Example 1	3.08																																									
Compound	UPTAKE (% ID/g)																																									
¹¹¹ In-Piotelete	5.03																																									
¹²⁵ I-Fibrinogen	0.105																																									
¹²⁵ I-Albumin	0.037																																									
Example 1	0.7																																									
Compound	Ratio																																									
¹¹¹ In-Piotelete	117																																									
¹²⁵ I-Fibrinogen	2.09																																									
¹²⁵ I-Albumin	0.454																																									
Example 1	114																																									

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NI	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

Informa Application No

PCT/US 97/03915

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K51/08 C07F13/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 22494 A (THE DU PONT MERCK PHARMACEUTICAL COMPANY) 13 October 1994 cited in the application see the whole document, especially pages 59-114, page 118 lines 29-34, examples 3 and 4 pages 319-320, pages 325-327 examples 12 and 15, page 338 lines 8-29 ---	1-14
A	US 5 350 837 A (G. J. BRIDGER) 27 September 1994 cited in the application see the whole document ---	1-5,7, 11-13
A	WO 92 05154 A (MALLINCKRODT MEDICAL INC.) 2 April 1992 see the whole document ---	1-5,7, 11-13
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

B document member of the same patent family

Date of the actual completion of the international search

19 December 1997

Date of mailing of the international search report

21. 01. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 apo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gac, G

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/03915

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 15771 A (MALLINCKRODT MEDICAL INC.) 19 August 1993 see the whole document ---	1-14
A	WO 94 16741 A (BURROUGHS WELLCOME CO.) 4 August 1994 see the whole document ---	1-14
A	WO 95 03280 A (RESOLUTION PHARMACEUTICALS INC.) 2 February 1995 see the whole document ---	1-14
A	HARRIS ET AL.: "Design and synthesis of Tc-99m labeled boroarginine thrombin inhibitors as potential thrombus imaging agents" J. NUCL. MED., vol. 35, no. sup5, May 1994, pages 241p-242p, XP002050941 see abstract nr 989 ---	1-14
A	LIU ET AL.: "Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as coligands" BIOCONJUGATE CHEM., vol. 7, no. 1, January 1996 - February 1996, pages 63-71, XP002050942 see the whole document ---	1-14
A	EDWARDS: "Potential 99mTc radiopharmaceuticals for renal imaging : Tris(N-substituted-3-hydroxy-2-methyl-4-py ridinato)technetium(IV) cations" NUCL. MED. BIOL., vol. 20, no. 7, October 1993, pages 857-863, XP002050943 see the whole document ---	1-14
P,A	WO 96 31243 A (THE DU PONT MERCK PHARMACEUTICAL COMPANY) 10 October 1996 see the whole document ---	1-14
P,A	WO 96 40637 A (THE DU PONT MERCK PHARMACEUTICAL COMPANY) 19 December 1996 see the whole document ---	1-14
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/03915

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	<p>RAJOPADHYE : "Synthesis, evaluation and Tc-99m complexation of a hydrazinonicotinyl conjugate of a GP IIb/IIIa antagonist cyclic peptide for the detection of deep vein thrombosis"</p> <p>BIOORG. MED. CHEM. LETT., vol. 7, no. 8, 1997, pages 955-960, XP002050944 see the whole document</p> <p>-----</p>	1-14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/03915

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 7-10
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/03915

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9422494 A	13-10-94	AU 3452595 A	21-03-96
		AU 6524894 A	24-10-94
		BG 100036 A	29-11-96
		BR 9406055 A	10-09-96
		BR 9406820 A	10-09-96
		CA 2159445 A	13-10-94
		CN 1122577 A	15-05-96
		EP 0692982 A	24-01-96
		FI 954655 A	02-11-95
		HU 72889 A	28-06-96
		JP 8509710 T	15-10-96
		LV 11106 B	20-04-97
		NO 953886 A	30-11-95
		NZ 263970 A	25-09-96
US 5350837 A	27-09-94	PL 311037 A	22-01-96
		ZA 9402262 A	02-10-95
		AU 3717393 A	04-11-93
		CA 2094380 A	03-11-93
		EP 0569132 A	10-11-93
		JP 6065169 A	08-03-94
WO 9205154 A	02-04-92	NZ 247445 A	26-07-95
		ZA 9302844 A	21-06-94
		AU 8721591 A	15-04-92
		IL 99485 A	27-11-95
WO 9315771 A	19-08-93	US 5656253 A	12-08-97
		US 5310536 A	10-05-94
		AU 3610593 A	03-09-93
		EP 0630264 A	28-12-94
		JP 7503732 T	20-04-95
WO 9416741 A	04-08-94	US 5656253 A	12-08-97
		AU 6128694 A	15-08-94
		EP 0681484 A	15-11-95
WO 9503280 A	02-02-95	JP 8509955 T	22-10-96
		AU 7261994 A	20-02-95
		CA 2167167 A	02-02-95

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/03915

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9503280 A		EP 0710228 A JP 9500140 T US 5659041 A	08-05-96 07-01-97 19-08-97
WO 9631243 A	10-10-96	AU 5787496 A HR 960148 A	23-10-96 31-10-97
WO 9640637 A	19-12-96	AU 6166196 A	30-12-96

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.